[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1387
1. Mannini A, Calzolari A, Calorini L, Mugnai G, Ruggieri S: The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis. Clin Exp Metastasis; 2006;23(3-4):159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis.
  • To this aim, in pulmonary colonies developed from B16-F10 cells in EFA-deficient animals or in animals fed a 5% corn oil diet, we performed an immunohistochemical analysis of bcl-2/bax proteins, PCNA, and VEGF and von Willebrand Factor (vWF), typical markers of apoptosis, proliferation, and angiogenesis, respectively.
  • [MeSH-major] Apoptosis. Fatty Acids, Essential / metabolism. Lung Neoplasms / secondary. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Neovascularization, Pathologic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2000;37(2):119-27 [11142082.001]
  • [Cites] Lipids. 1979 Feb;14(2):247-52 [423723.001]
  • [Cites] J Nutr. 1998 Feb;128(2 Suppl):427S-433S [9478042.001]
  • [Cites] Exp Cell Res. 1977 Feb;104(2):255-62 [65285.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6557-62 [7987856.001]
  • [Cites] Am J Clin Nutr. 1997 Oct;66(4 Suppl):998S-1003S [9322580.001]
  • [Cites] Clin Exp Metastasis. 1998 Jul;16(5):407-14 [10091936.001]
  • [Cites] Cancer Metastasis Rev. 1994 Dec;13(3-4):285-302 [7712591.001]
  • [Cites] Biochim Biophys Acta. 1984 Sep 12;795(2):196-207 [6548159.001]
  • [Cites] Lipids. 1979 Apr;14(4):407-12 [440031.001]
  • [Cites] Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:843-6 [1825423.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Sep;65(3):123-31 [11728162.001]
  • [Cites] Acta Neurochir (Wien). 2004 May;146(5):483-94 [15118886.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):305-13 [12679317.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):857-62 [2643465.001]
  • [Cites] J Lipid Res. 1981 May;22(4):590-7 [6268724.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):147-54 [14703061.001]
  • [Cites] Annu Rev Nutr. 2005;25:549-71 [16011478.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1988;34(3):229-37 [3065787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7961-5 [7644521.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):1078-87 [9378543.001]
  • [Cites] Lipids. 1978 Dec;13(12):892-7 [750830.001]
  • [Cites] Invasion Metastasis. 1992;12(3-4):233-40 [1338202.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 2):4091-100 [100216.001]
  • [Cites] FEBS Lett. 1998 Jul 17;431(2):224-6 [9708907.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Nutr Cancer. 1989;12(4):343-50 [2608539.001]
  • [Cites] J Intern Med. 2001 May;249(5):395-411 [11350564.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Oct 16;164(1):277-83 [2803300.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 1):5252-6 [3876880.001]
  • [Cites] Lipids. 1992 Oct;27(10):793-7 [1435097.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5241-6 [8643560.001]
  • [Cites] Proc Soc Exp Biol Med. 1983 Feb;172(2):214-8 [6572402.001]
  • [Cites] J Natl Cancer Inst. 1987 Aug;79(2):351-8 [3474466.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182-7 [9789062.001]
  • [Cites] Trends Biochem Sci. 1993 Aug;18(8):307-9 [8236446.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4686-90 [8402646.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] Cell Immunol. 1986 Apr 15;99(1):108-18 [2944621.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6642-7 [3180073.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] J Clin Pathol. 2006 May;59(5):492-6 [16489179.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6441-5 [7987840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Oct;71(10):3976-8 [4530277.001]
  • [Cites] Cancer Lett. 1988 Dec 1;43(1-2):111-20 [3203321.001]
  • [Cites] Am J Clin Nutr. 1987 Jan;45(1 Suppl):218-24 [3799514.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4714-9 [6576855.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):935-45 [15159222.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):893-913 [9714178.001]
  • [Cites] Cell Biol Int Rep. 1989 Sep;13(9):813-4 [2805090.001]
  • [Cites] Cancer Res. 1971 Feb;31(2):91-7 [5545273.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):215-27 [12741680.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:64-7 [10807405.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6171-5 [3677068.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2304-11 [10733500.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):631-42 [14601637.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6323-8 [12414664.001]
  • (PMID = 17028925.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fatty Acids, Essential
  •  go-up   go-down


2. Smagur A, Boyko MM, Biront NV, Cichoń T, Szala S: Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth. Acta Biochim Pol; 2009;56(1):115-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth.
  • Experiments in vivo demonstrated that ABRaA-VEGF(121) inhibits growth of B16-F10 murine melanoma tumors.
  • [MeSH-major] Abrin / pharmacology. Cell Division / drug effects. Melanoma, Experimental / pathology. Recombinant Fusion Proteins / pharmacology. Vascular Endothelial Growth Factor A / pharmacology. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • Hazardous Substances Data Bank. ABRIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252752.001).
  • [ISSN] 0001-527X
  • [Journal-full-title] Acta biochimica Polonica
  • [ISO-abbreviation] Acta Biochim. Pol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A; 1393-62-0 / Abrin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


3. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R: Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther; 2010 Feb;17(2):158-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
  • In this respect, injection of oncolytic vesicular stomatitis virus (VSV) into subcutaneous B16ova melanomas in C57Bl/6 mice leads to tumor regression, but it is not associated with viral replicative burst in the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2008 Jan;16(1):146-53 [18071337.001]
  • [Cites] Curr Med Chem. 2007;14(12):1279-89 [17504213.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Feb;19(1):79-92 [18155952.001]
  • [Cites] Gene Ther. 2008 Apr;15(8):604-16 [18305577.001]
  • [Cites] Virology. 2008 Jun 20;376(1):165-72 [18396306.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7358-66 [19010851.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):1910-8 [18827807.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57 [17077357.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6391-5 [11103803.001]
  • [Cites] IUBMB Life. 2000 Aug;50(2):135-8 [11185959.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] Nat Med. 2001 Jul;7(7):781-7 [11433341.001]
  • [Cites] J Virol. 1993 Jul;67(7):3917-22 [8389912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81 [7753828.001]
  • [Cites] Mol Med Today. 1996 Dec;2(12):519-27 [9015793.001]
  • [Cites] Cell. 1997 Sep 5;90(5):849-57 [9298897.001]
  • [Cites] J Immunother. 1998 May;21(3):211-7 [9610913.001]
  • [Cites] J Virol. 1999 Aug;73(8):6937-45 [10400792.001]
  • [Cites] Hepatology. 2005 Jan;41(1):196-203 [15619242.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Sep;5(6):381-92 [16178815.001]
  • [Cites] J Virol. 2005 Nov;79(21):13231-8 [16227246.001]
  • [Cites] J Virol. 2005 Dec;79(24):15043-53 [16306575.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5495-504 [12359759.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):938-50 [12459732.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3605-11 [12839948.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):263-75 [14585354.001]
  • [Cites] Mol Ther. 2004 Mar;9(3):368-76 [15006603.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] Drug Discov Today. 2004 Sep 1;9(17):759-68 [15450242.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):965-76 [16294217.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34064-71 [16973618.001]
  • [Cites] Nat Med. 2007 Mar;13(3):354-60 [17334371.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • [Cites] Nat Med. 2008 Jan;14(1):37-44 [18066076.001]
  • (PMID = 20016540.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066726; United States / NCI NIH HHS / CA / CA66726-12; United States / NCI NIH HHS / CA / R01 CA107082; United States / NCI NIH HHS / CA / CA107082-02; United States / NCI NIH HHS / CA / R01 CA132734; United States / NCI NIH HHS / CA / CA130878-01; United States / NCI NIH HHS / CA / R01 CA130878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral
  • [Other-IDs] NLM/ NIHMS150322; NLM/ PMC3934361
  •  go-up   go-down


Advertisement
4. Belleri M, Ribatti D, Savio M, Stivala LA, Forti L, Tanghetti E, Alessi P, Coltrini D, Bugatti A, Mitola S, Nicoli S, Vannini V, Presta M: alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Mol Cancer Ther; 2008 Dec;7(12):3761-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, trans-resveratrol inhibits vascularization of the chick embryo area vasculosa and murine melanoma B16 tumor growth and neovascularization.
  • [MeSH-minor] Animals. Cattle. Chick Embryo. Endothelial Cells / cytology. Female. Humans. Melanoma, Experimental / drug therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Stereoisomerism

  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074851.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Phytogenic; 0 / Integrin alphaVbeta3; 0 / Stilbenes; Q369O8926L / resveratrol
  •  go-up   go-down


5. Girard TJ: A factor X-TFPI hybrid protein inhibits B16 melanoma metastatic growth in mice. Thromb Res; 2007;121(3):427-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A factor X-TFPI hybrid protein inhibits B16 melanoma metastatic growth in mice.
  • [MeSH-major] Factor X / pharmacology. Lipoproteins / pharmacology. Melanoma, Experimental / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555803.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipoproteins; 0 / Recombinant Fusion Proteins; 0 / lipoprotein-associated coagulation inhibitor; 9001-29-0 / Factor X
  •  go-up   go-down


6. Kim SJ, Kim BS, Kyung TW, Lee SC, Rho CW, Choi KR, Hwang HJ, Choi HS: Suppressive effects of young radish cultivated with sulfur on growth and metastasis of B16-F10 melanoma cells. Arch Pharm Res; 2006 Mar;29(3):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressive effects of young radish cultivated with sulfur on growth and metastasis of B16-F10 melanoma cells.
  • Sulforaphane, which could be a candidate for an active compound from young radishes cultivated with sulfur, inhibited cell growth of B16-F10 melanoma cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy. Plant Extracts / pharmacology. Raphanus

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596997.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Isothiocyanates; 0 / Plant Extracts; 0 / Thiocyanates; 4478-93-7 / sulforafan; 70FD1KFU70 / Sulfur; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


7. Guo H, Shenoy N, Gershman BM, Yang J, Sklar LA, Miao Y: Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl Med Biol; 2009 Apr;36(3):267-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.
  • INTRODUCTION: The purpose of this study was to examine whether a novel lactam bridge-cyclized (111)In-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Gly-Glu-c[Lys-Nle-Glu-His-d-Phe-Arg-Trp-Gly-Arg-Pro-Val-Asp] {DOTA-GlyGlu-CycMSH} could be an effective imaging probe for metastatic melanoma detection.
  • The internalization and efflux of (111)In-DOTA-GlyGlu-CycMSH were examined in B16/F10 melanoma cells.
  • The biodistribution of (111)In-DOTA-GlyGlu-CycMSH was determined in B16/F10 pulmonary metastatic melanoma-bearing and normal C57 mice.
  • Pulmonary metastatic melanoma imaging was performed by small-animal single-photon emission computed tomography (SPECT)/CT (Nano-SPECT/CT) using (111)In-DOTA-GlyGlu-CycMSH as an imaging probe and compared with 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) positron emission tomography (PET) imaging.
  • RESULTS: (111)In-DOTA-GlyGlu-CycMSH was readily prepared with greater than 95% radiolabeling yield. (111)In-DOTA-GlyGlu-CycMSH displayed rapid internalization and extended efflux in B16/F10 cells. (111)In-DOTA-GlyGlu-CycMSH exhibited significantly (P<.05) higher uptakes (2.00+/-0.74%ID/g at 2 h post-injection and 1.83+/-0.12%ID/g at 4 h post-injection) in metastatic melanoma-bearing lung than that in normal lung (0.08+/-0.08%ID/g and 0.05+/-0.05%ID/g at 2 and 4 h post-injection, respectively).
  • B16/F10 pulmonary melanoma metastases were clearly visualized with (111)In-DOTA-GlyGlu-CycMSH 2 h post-injection rather than with [(18)F]FDG 1 h post-injection.
  • CONCLUSIONS: (111)In-DOTA-GlyGlu-CycMSH exhibited favorable metastatic melanoma-targeting and -imaging properties, highlighting its potential as an effective imaging probe for metastatic melanoma detection.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3549-59 [10589771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):1751-5 [6281785.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):248-56 [11216523.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):628-33 [11340564.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] J Nucl Med Technol. 2002 Mar;30(1):3-9; quiz 10-1 [11948260.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):683-93 [12209157.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):480-7 [12216078.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):546-56 [12217792.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):336-51 [12353250.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4763-5 [12941790.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1561-5 [14530467.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Cancer Res. 1975 Jan;35(1):218-24 [1109790.001]
  • [Cites] Endocrinology. 1987 Nov;121(5):1900-7 [2822378.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6876-81 [3180096.001]
  • [Cites] Cancer Res. 1989 Nov 15;49(22):6352-8 [2804981.001]
  • [Cites] J Med Chem. 1989 Dec;32(12):2555-61 [2555512.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3B):1803-8 [9179237.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):792-5 [9211767.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):417-8 [9482300.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4979-86 [15958536.001]
  • [Cites] Curr Opin Chem Biol. 2005 Aug;9(4):352-8 [16023401.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] Mol Imaging. 2006 Apr-Jun;5(2):105-14 [16954024.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1206-11 [10655509.001]
  • (PMID = 19324272.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118100-01; United States / NCI NIH HHS / CA / P30 CA118100; United States / NCI NIH HHS / CA / P30 CA118100-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 1-Ring; 0 / Indium Radioisotopes; 0 / Lactams; 0 / Peptides, Cyclic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 581-05-5 / alpha-MSH; 60239-18-1 / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
  • [Other-IDs] NLM/ NIHMS108141; NLM/ PMC2685149
  •  go-up   go-down


8. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res; 2006 Apr 15;66(8):4468-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.
  • We showed that, similar to their human orthologues, mIFN-lambda2 and mIFN-lambda3 signal through the IFN-lambda receptor complex, activate IFN stimulated gene factor 3, and are capable of inducing antiviral protection and MHC class I antigen expression in several cell types including B16 melanoma cells.
  • We then used the murine B16 melanoma model to investigate the potential antitumor activities of IFN-lambdas.
  • We developed B16 cells constitutively expressing murine IFN-lambda2 (B16.IFN-lambda2 cells) and evaluated their tumorigenicity in syngeneic C57BL/6 mice.
  • Although constitutive expression of mIFN-lambda2 in melanoma cells did not affect their proliferation in vitro, the growth of B16.IFN-lambda2 cells, when injected s.c. into mice, was either retarded or completely prevented.
  • We then developed IFN-lambda-resistant B16.IFN-lambda2 cells (B16.IFN-lambda2Res cells) and showed that their tumorigenicity was also highly impaired or completely abolished similar to B16.IFN-lambda2 cells, suggesting that IFN-lambdas engage host mechanisms to inhibit melanoma growth.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618774.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI051139; United States / NIAID NIH HHS / AI / R01 AI057468; United States / NIAID NIH HHS / AI / AI057468; United States / NIEHS NIH HHS / ES / ES05022
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Interferon; 9008-11-1 / Interferons
  •  go-up   go-down


9. Wang JF, Su RB, Wu N, Xu B, Lu XQ, Liu Y, Li J: Inhibitory effect of agmatine on proliferation of tumor cells by modulation of polyamine metabolism. Acta Pharmacol Sin; 2005 May;26(5):616-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similar results were obtained in the transplanted B16 melanoma tumor model.
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. L-Lactate Dehydrogenase / metabolism. Male. Melanoma, Experimental / pathology. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Transplantation. Putrescine / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Putrescine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842783.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Polyamines; 70J407ZL5Q / Agmatine; EC 1.1.1.27 / L-Lactate Dehydrogenase; V10TVZ52E4 / Putrescine
  •  go-up   go-down


10. Cuff S, Dolton G, Matthews RJ, Gallimore A: Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. J Immunol; 2010 Jan 15;184(2):607-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the melanoma cell line B16 as a murine model of pulmonary metastasis, we examined whether the pro- versus antitumoral effects of CD8+ T cells relate to their Ag specificity.
  • [MeSH-major] Antigens / immunology. CD8-Positive T-Lymphocytes / immunology. Melanoma / immunology. T-Cell Antigen Receptor Specificity / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007540.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 067046; United Kingdom / Medical Research Council / / G117/488; United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Antigens, Viral; 9006-59-1 / Ovalbumin
  •  go-up   go-down


11. Capobianco A, Rovere-Querini P, Rugarli C, Manfredi AA: Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J Cancer; 2006 Dec 15;119(12):2861-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells.
  • Here, we show that B16 melanoma cells actively modulate the interaction between DCs derived from bone marrow precursors and NK/LAK cells propagated from the spleen of C57BL/6 mice.
  • DCs increased in a dose-dependent manner the ability of NK/LAK cells to kill melanoma cells and to produce cytokines.
  • Melanoma cells were not a passive target of NK activity; they regulated the outcome of the interaction between DCs and NK/LAK cells, inhibiting the in vitro production of cytokines as effectively as the genetic deletion of IL-18 or IFN-gamma.
  • [MeSH-major] Dendritic Cells / metabolism. Killer Cells, Lymphokine-Activated / metabolism. Killer Cells, Natural / metabolism. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16998790.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


12. Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, Reiser CO, Hess J: Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother; 2005 Jun;54(6):611-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma.
  • Polyomavirus-like-particles (PLPs) are empty, non-replicative, non-infectious particles that represent a potent antigen-delivery system against malignant disease.
  • These PPs displaying an immunodominant H-2Kb-restricted ovalbumin (OVA)257-264 epitope evoked nearly complete tumour remission in MO5 (B16-OVA) melanoma-bearing C57BL/6 mice by two s.c. applications in a weekly interval.
  • The immunotherapeutic intervention started at day 4 after melanoma implant.
  • Furthermore, 40% of melanoma-bearing mice vaccinated with heterologous PPs carrying a H-2Kb-restricted cytotoxic T lymphocyte (CTL) epitope derived from of tyrosinase-related protein 2 (TRP2) survived similar treatment conditions.
  • However, a late immunotherapeutic onset at day 10 post melanoma inoculation revealed no significant differences between the therapeutic values (40-60% survival) of VP1-OVA252-270 and VP1-TRP2180-192 PPs, respectively.
  • As a correlate for preventive and therapeutic immunity against MO5 melanoma the number of OVA257-264- or TRP2180-188-specific CD8 T cells were significantly increased within the splenocyte population of treated mice as measured by H-2Kb-OVA257-264-PE tetramer staining or appropriate ELISPOT assays, respectively.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Capsid Proteins / immunology. Epitopes, T-Lymphocyte. Melanoma, Experimental / therapy. Polyomavirus / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685447.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / Epitopes, T-Lymphocyte; 0 / Peptide Fragments; 9006-59-1 / Ovalbumin
  •  go-up   go-down


13. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst; 2008 Oct 15;100(20):1464-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
  • BACKGROUND: Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1.
  • METHODS: B16 mouse skin melanoma cells, which are deficient in MCP-1 expression, and mouse Lewis lung cancer (LLC) cells, which express high levels of MCP-1, were engineered to stably express MCP-1 and short hairpin RNAs (shRNAs) targeting the MCP-1 transcript, respectively.
  • Overexpression of MCP-1 in intrapleurally injected B16 melanoma cells led to increased MPE and reduced survival.
  • CONCLUSION: MCP-1 produced by tumor cells is an important determinant of their capacity to induce the formation of MPE and may be a useful target for the treatment of malignant pleural disease.
  • [MeSH-major] Chemokine CCL2 / biosynthesis. Neoplasms, Experimental / immunology. Pleural Effusion, Malignant / immunology
  • [MeSH-minor] Animals. Capillary Permeability. Carcinoma, Lewis Lung / blood supply. Carcinoma, Lewis Lung / genetics. Carcinoma, Lewis Lung / immunology. Carcinoma, Lewis Lung / pathology. Cell Line, Tumor. Disease Models, Animal. Female. Macrophages / immunology. Macrophages / pathology. Male. Melanoma, Experimental / blood supply. Melanoma, Experimental / genetics. Melanoma, Experimental / immunology. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Neovascularization, Pathologic / immunology. Neovascularization, Pathologic / pathology. Plasmids / genetics. RNA, Small Interfering / genetics. Skin Neoplasms / blood supply. Skin Neoplasms / genetics. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840818.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CCL2; 0 / RNA, Small Interfering
  •  go-up   go-down


14. Akazawa H, Fujita Y, Banno N, Watanabe K, Kimura Y, Manosroi A, Manosroi J, Akihisa T: Three new cyclic diarylheptanoids and other phenolic compounds from the bark of Myrica rubra and their melanogenesis inhibitory and radical scavenging activities. J Oleo Sci; 2010;59(4):213-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten cyclic diarylheptanoids (1-10), including three new compounds: myricanone 5-O-alpha-L-arabinofuranosyl-(1-->6)-beta-D-glucopyranoside (7), myricanone 17-O-beta-D-(6'-O-galloyl)-glucopyranoside (8), and 16-methoxy acerogenin B 9-O-beta-D-apiofuranosyl-(1-->6)-beta-D-glucopyranoside (10), along with two flavonoids (11, 12), were isolated from the extracts of Myrica rubra (Myricaceae) bark.
  • On evaluation of compounds 1-12 against the melanogenesis in the B16 melanoma cells, six compounds, 3, 5, 7, 8, 10, and 12, exhibited inhibitory effects with 30-56% reduction of melanin content at 25 microg/mL with no or very weak toxicity to the cells (82-103% of cell viability at 25 microg/mL).
  • [MeSH-major] Diarylheptanoids / isolation & purification. Diarylheptanoids / pharmacology. Free Radical Scavengers. Melanins / metabolism. Melanoma, Experimental / metabolism. Myricaceae / chemistry. Phenols / isolation & purification. Phenols / pharmacology. Plant Extracts / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299768.001).
  • [ISSN] 1347-3352
  • [Journal-full-title] Journal of oleo science
  • [ISO-abbreviation] J Oleo Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biphenyl Compounds; 0 / Diarylheptanoids; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Melanins; 0 / Phenols; 0 / Picrates; 0 / Plant Extracts; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl
  •  go-up   go-down


15. Torabian SZ, de Semir D, Nosrati M, Bagheri S, Dar AA, Fong S, Liu Y, Federman S, Simko J, Haqq C, Debs RJ, Kashani-Sabet M: Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis. Am J Pathol; 2009 Mar;174(3):1009-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.
  • We examined the consequences of targeting IkappaBgamma in melanoma cells using a hammerhead ribozyme.
  • We developed stable transformant B16-F10 melanoma cell lines that express a ribozyme that targets mouse IkappaBgamma (IkappaBgamma-144-Rz).
  • Tail-vein injection of B16-F10 cells that stably express IkappaBgamma-144-Rz into mice resulted in a significant reduction of the metastatic potential of these cells.
  • IkappaBgamma-144-Rz-expressing B16 cells were shown to have increased transcriptional activity of nuclear factor-kappaB.
  • We then showed that IkappaBgamma-144-Rz-expressing cells demonstrated both reduced invasion and increased apoptosis, suggesting the existence of pathways through which IkappaBgamma promotes melanoma metastasis.
  • Plasmid-mediated expression of IkappaBgamma-144-Rz produced a significant inhibition of the metastatic progression of B16-F10 cells to the lung and resulted in significant anti-invasive and pro-apoptotic effects on murine Lewis lung carcinoma cells.
  • Our results suggest a novel role for IkappaBgamma in promoting the metastatic progression of melanoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8255-9 [11788578.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):892-7 [10786798.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3878-83 [11891271.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):639-43 [12571598.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):1039-45 [12495434.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14(2):64-9 [15102437.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4983-90 [15297398.001]
  • [Cites] EMBO J. 1991 Dec;10(13):4159-67 [1756723.001]
  • [Cites] Cell. 1992 Mar 20;68(6):1109-20 [1339305.001]
  • [Cites] Cell. 1992 Mar 20;68(6):1121-33 [1547506.001]
  • [Cites] Nucleic Acids Res. 1992 May 25;20(10):2453-8 [1598203.001]
  • [Cites] Nucleic Acids Res. 1993 Sep 25;21(19):4516-23 [7694229.001]
  • [Cites] J Cell Sci Suppl. 1994;18:19-33 [7883789.001]
  • [Cites] Genes Dev. 1995 Nov 15;9(22):2723-35 [7590248.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Virchows Arch. 2004 Nov;445(5):515-20 [15378359.001]
  • [Cites] Neurosci Lett. 2005 Jan 10;373(2):115-8 [15567564.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(3):1113-23 [15657437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7 [15833814.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):301-13 [15986139.001]
  • [Cites] FEBS J. 2005 Jul;272(14):3505-11 [16008551.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10071-8 [16260620.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8093-104 [16044147.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):812-9 [16424013.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):759-72 [16410803.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6579-88 [16818630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11306-11 [16847266.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8382-8 [16951147.001]
  • [Cites] Melanoma Res. 2006 Oct;16(5):435-44 [17013093.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):37142-9 [16966325.001]
  • [Cites] Anticancer Drugs. 2007 Feb;18(2):105-10 [17159597.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7624-31 [17224454.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11093-8 [18056430.001]
  • [Cites] Int Rev Immunol. 2008;27(4):183-204 [18574736.001]
  • [Cites] Nat Immunol. 2002 Mar;3(3):221-7 [11875461.001]
  • (PMID = 19179607.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114337-04; United States / NCI NIH HHS / CA / R01 CA114337; United States / NCI NIH HHS / CA / R01 CA114337-03; United States / NCI NIH HHS / CA / CA122947; United States / NCI NIH HHS / CA / CA122947-02; United States / NCI NIH HHS / CA / R01 CA122947-03; United States / NCI NIH HHS / CA / R01 CA114337-04; United States / NCI NIH HHS / CA / R01 CA122947; United States / NCI NIH HHS / CA / CA114337-03; United States / NCI NIH HHS / CA / CA122947-03; United States / NCI NIH HHS / CA / R01 CA122947-02; United States / NCI NIH HHS / CA / CA114337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / NF-kappa B p50 Subunit; 0 / RNA, Catalytic; 0 / RNA, Neoplasm; 147257-52-1 / Nfkb1 protein, mouse
  • [Other-IDs] NLM/ PMC2665760
  •  go-up   go-down


16. Torres D, Paget C, Fontaine J, Mallevaey T, Matsuoka T, Maruyama T, Narumiya S, Capron M, Gosset P, Faveeuw C, Trottein F: Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. J Immunol; 2008 Jan 15;180(2):783-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma.
  • We also report that PGD2 and BW245C (a selective DP1 agonist) reduce the protective effects of alpha-GalCer in B16F10-induced melanoma metastasis, an effect that depends on IFN-gamma production by iNKT cells.
  • [MeSH-major] Interferon-gamma / antagonists & inhibitors. Killer Cells, Natural / drug effects. Melanoma, Experimental / immunology. Prostaglandin D2 / pharmacology. Skin Neoplasms / immunology. T-Lymphocytes / drug effects


17. Xiong XB, Huang Y, Lü WL, Zhang X, Zhang H, Zhang Q: [Preparation of doxorubicin-loaded stealth liposomes modified with RGD mimetic and cellular association in vitro]. Yao Xue Xue Bao; 2005 Dec;40(12):1085-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pH-sensitive probe, BCECF-AM, was used to study the binding of melanoma cells to DSPE-PEG-RGDm.
  • RESULTS: The melanoma cells A375 and B16 showed enhanced binding to the immobilized DSPE-PEG-RGDm.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Doxorubicin / administration & dosage. Melanoma, Experimental / pathology. Oligopeptides

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496670.001).
  • [ISSN] 0513-4870
  • [Journal-full-title] Yao xue xue bao = Acta pharmaceutica Sinica
  • [ISO-abbreviation] Yao Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 0 / Oligopeptides; 0 / Phosphatidylethanolamines; 1G4B5265CQ / 1,2-distearoylphosphatidylethanolamine; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 99896-85-2 / arginyl-glycyl-aspartic acid
  •  go-up   go-down


18. Carosio R, Zuccari G, Orienti I, Mangraviti S, Montaldo PG: Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer; 2007;6:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sodium ascorbate has been recently reported to induce apoptosis of B16 melanoma cells through down-regulation of the transferrin receptor, CD71.
  • Since NB and melanoma share the same embryologic neuroectodermal origin, we used different human NB cell lines to assess whether the same findings occurred.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. Trypan blue .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2000 Aug 25;259(1):308-13 [10942603.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1073-9 [11221835.001]
  • [Cites] Nat Struct Biol. 2001 May;8(5):394-401 [11323712.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Ann Intern Med. 2004 Apr 6;140(7):533-7 [15068981.001]
  • [Cites] P R Health Sci J. 2004 Jun;23(2):115-8 [15377059.001]
  • [Cites] Cancer Res. 1970 Aug;30(8):2110-8 [5459762.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2643-52 [4748425.001]
  • [Cites] Chem Biol Interact. 1974 Oct;9(4):285-315 [4430016.001]
  • [Cites] Chem Biol Interact. 1975 Nov;11(5):387-93 [1104207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685-9 [1068480.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Sep;75(9):4538-42 [279931.001]
  • [Cites] N Engl J Med. 1979 Sep 27;301(13):687-90 [384241.001]
  • [Cites] Ann Intern Med. 1982 Dec;97(6):873-84 [6756240.001]
  • [Cites] Blood. 1984 Sep;64(3):748-53 [6380622.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):137-41 [3880867.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2843-8 [3986811.001]
  • [Cites] Cancer Res. 1987 Feb 1;47(3):747-53 [3802079.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):578-9 [2307545.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6295-301 [2400993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3671-5 [2023917.001]
  • [Cites] Life Sci. 1992;50(26):2059-65 [1608289.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):475-80 [8517665.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Nov 30;197(1):40-5 [8250945.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26200-5 [8253740.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):379-85 [8707412.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2529-37 [9192836.001]
  • [Cites] Carcinogenesis. 1997 Jul;18(7):1389-94 [9230285.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Biochim Biophys Acta. 1997 Mar 14;1331(1):1-40 [9325434.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Mar;39(3):631-3 [9501875.001]
  • [Cites] Chem Biol. 1998 May;5(5):R97-103 [9578633.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):146-56 [15578707.001]
  • [Cites] In Vivo. 2005 Jan-Feb;19(1):233-6 [15796180.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):192-7 [15672419.001]
  • [Cites] Annu Rev Nutr. 2005;25:105-25 [16011461.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):129-43 [10726979.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9303-7 [10734071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9 [16157892.001]
  • (PMID = 17760959.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antioxidants; 0 / Receptors, Transferrin; E1UOL152H7 / Iron; EC 3.4.22.- / Caspases; I2ZWO3LS3M / Trypan Blue; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ PMC2000471
  •  go-up   go-down


19. Taga M, Yamauchi K, Odle J, Furian L, Sundaresan A, Ramesh GT, Pellis NR, Andrassy RJ, Kulkarni AD: Melanoma growth and tumorigenicity in models of microgravity. Aviat Space Environ Med; 2006 Nov;77(11):1113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma growth and tumorigenicity in models of microgravity.
  • METHODS: Murine B16-F10 melanoma cells were cultured in a tissue culture flask (FL) and in a rotating-wall vessel bioreactor (BIO) designed by NASA to simulate some aspects of microgravity.
  • After 48 h of cultures in FL and BIO, cells were inoculated subcutaneously in C57BL/6 mice, syngeneic hosts for B16-F10 tumor cells.
  • When BIO-cultured melanoma cells were inoculated subcutaneously in mice, there was a significant increase in tumorigenicity as compared with FL-cultured cells.
  • [MeSH-major] Melanoma, Experimental / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086762.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


20. Wolf M, Eskerski H, Bauder-Wüst U, Haberkorn U, Eisenhut M: Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. Melanoma Res; 2006 Dec;16(6):487-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
  • The in-vivo antineoplastic potential of the alkylating N-(2-dialkylaminoethyl)benzamides BZA1 and BZA2, novel melanoma targeted anticancer drugs, was evaluated in a mouse melanoma model with nude mice bearing subcutaneous SkMel28, B16 or WM266-4.
  • Treatment was initiated with an intraperitoneal injection of 8 mg/kg of BZA1 or BZA2 on days 0, 2 and 4 in the case of B16 melanoma on days 0, 1 and 2 after the onset of the experiment, when the mean tumor diameter ranged within 4-6 mm.
  • Significant tumor growth delay was observed under BZA1, BZA2 and dacarbazine treatment compared with the untreated control group in all three evaluated melanomas with insignificant differences among BZA1, BZA2 and dacarbazine.
  • The insignificant effect of chlorambucil and the strong improvement on growth delay achieved with BZA1 and BZA2 demonstrated melanoma targeting characteristics of the N-(2-dialkylaminoethyl)benzamide structure element.
  • [MeSH-major] Benzamides / therapeutic use. Disease Models, Animal. Melanoma, Experimental / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119449.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Benzamides; 106790-96-9 / N-(2-(diethylamino)ethyl)-4-iodobenzamide; 18D0SL7309 / Chlorambucil; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


21. Olszewska-Słonina DM, Styczyńisk J, Drewa TA, Olszewski KJ, Czajkowski R: B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment. Acta Pol Pharm; 2005 Nov-Dec;62(6):473-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
  • The aim of this study was to determine the influence of dacarbazine (DTIC) on morphology and kinetics of proliferation of B16 and Cloudman S91 cells.
  • The evaluation of apoptosis and necrosis in these two mouse melanoma cell lines in vitro was performed.
  • The highest induction of apoptosis was observed in DTIC concentration of 200 microg/mL for B16 cells (11%) and 100 microg/mL for apoptosis Cloudman S91 cells (22.2%).
  • The B16 melanoma cells are more sensitive to DTIC than the Cloudman S91 cells, however more intensive apoptotic process was detected in Cloudman S91 cells already at lower concentration of DTIC.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Resistance, Neoplasm. Flow Cytometry. Melanoma, Experimental / pathology. Mice. Microscopy, Phase-Contrast

  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583988.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


22. Kim JH, Chen J, Majumder N, Lin H, Falo LD Jr, You Z: 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther; 2005 Oct;12(20):1517-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consistent with these findings, enhanced protection and significant therapeutic immunity to B16 melanoma was generated by this coimmunization strategy, which also augmented therapeutic immunity to GL-26 tumor.
  • In this B16 melanoma model, results from animal experiments with depletion of immune cells indicate that CD8+ T cells and NK cells are important in the antitumor immunity induced by this coimmunization strategy.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / administration & dosage. Genetic Therapy / methods. Melanoma, Experimental / therapy. Vaccines, DNA / administration & dosage. bcl-X Protein / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052205.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / Antigens, Neoplasm; 0 / Autoantigens; 0 / Cancer Vaccines; 0 / HSP70 Heat-Shock Proteins; 0 / Vaccines, DNA; 0 / bcl-X Protein; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


23. Bogo D, de Matos MF, Honda NK, Pontes EC, Oguma PM, da Santos EC, de Carvalho JE, Nomizo A: In vitro antitumour activity of orsellinates. Z Naturforsch C; 2010 Jan-Feb;65(1-2):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cytotoxicity assay was carried out in vitro with sulforhodamine B (SRB) using HEp-2 larynx carcinoma, MCF7 breast carcinoma, 786-0 kidney carcinoma, and B16-F10 murine melanoma cell lines, in addition to a normal (Vero) cell line in order to calculate the selectivity index of the compounds. n-Butyl orsellinate was the most active compound, with IC50 values (the concentration that inhibits 50% of growth) ranging from 7.2 to 14.0 microg/mL, against all the cell lines tested.
  • The compound was more active (IC50 = 11.4 microg/mL) against B16-F10 cells than was cisplatin (12.5 microg/mL).
  • Ethyl orsellinate was more active against HEp-2 than against MCF7, 786-0, or B16-F10 cells.
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cell Adhesion. Cell Line, Tumor. Cercopithecus aethiops. Female. History, Medieval. Humans. Melanoma, Experimental / drug therapy. Models, Molecular

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20355320.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Resorcinols; 0 / Salicylates; 11XLA0494B / orsellinic acid; 480-56-8 / lecanoric acid
  •  go-up   go-down


24. Agger R, Petersen MS, Petersen CC, Hansen SB, Stødkilde-Jørgensen H, Skands U, Blankenstein T, Andersen TE, Hulgaard EF, Jørgensen JT, Marqversen J, Gundersen HJ, Hokland ME: T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. J Immunother; 2007 Jan;30(1):29-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transgenic CD8+ T cells, specific for the ovalbumin peptide SIINFEKL, were adoptively transferred to recipients carrying a subcutaneous tumor of the ovalbumin-expressing malignant melanoma cell line B16-OVA.
  • By applying the combined positron emission tomography/magnetic resonance imaging technique we were able to determine the position of the transferred, 124I-labeled SIINFEKL-specific T cells in 3 dimensions in recipient mice, and could demonstrate a highly significant accumulation of the 124I label in and around the subcutaneous B16-OVA tumors compared with normal tissue.
  • Accumulation of 124I was significantly higher in B16-OVA than in B16 tumors not expressing the OVA antigen.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Immunotherapy, Adoptive / methods. Melanoma, Experimental / immunology. Receptors, Lymphocyte Homing / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198081.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Egg Proteins; 0 / Iodine Radioisotopes; 0 / OVA-8; 0 / Peptide Fragments; 0 / Receptors, Lymphocyte Homing; 9006-59-1 / Ovalbumin
  •  go-up   go-down


25. Xu JY, Gu Q, Xia WJ: [Effect of Spatholobus suberctus on adhesion, invasion, migration and metastasis of melanoma cells]. Zhong Yao Cai; 2010 Oct;33(10):1595-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of Spatholobus suberctus on adhesion, invasion, migration and metastasis of melanoma cells].
  • OBJECTIVE: To study the effect of Spatholobus suberctus, a kind of Chinese Traditional Medicine which can dissolve the stasis by activating the blood circulation, on invasion, adhesion, migration and metastasis of B16-BL6 metastatic mouse melanoma cells and its mechanism.
  • METHODS: The proliferation, adhesion, invasion and migration capacity of B16-BL6 metastatic cells was evaluated by MTP assay, adhesion assay and reconstituted basement membrane invasion and migration assay in vitro respectively.
  • Mouse spontaneous motility melanoma model was used to study the effect of Spatholobus suberctus on metastasis in vivo.
  • RESULTS: At the highest innoxious concentration, the extracts of Spatholobus suberctus inhibited the adhesion and invasion capacity of B16-BL6 metastatic cells significantly.
  • In the mouse spontaneous melanoma model, the lung metastatic nodes number and its volume were significantly decreased after continuously treated with the extracts of Spatholobus suberctu.
  • CONCLUSION: The extracts of Spatholobus suberctu can inhibit the metastasis of of B16-BI6 metastatic mouse melanoma cells and its mechanism may be inhibiting the capability of B16-BL6 cells in adhering to the ECM and invading the basement membrane.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Drugs, Chinese Herbal / pharmacology. Fabaceae / chemistry. Melanoma, Experimental / pathology. Neoplasm Metastasis / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21355199.001).
  • [ISSN] 1001-4454
  • [Journal-full-title] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
  • [ISO-abbreviation] Zhong Yao Cai
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


26. Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD: Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother; 2009 Oct;58(10):1565-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
  • These T cells were also tested for anti-tumor activity against melanoma lung metastases established by prior i.v. injection of B16 melanoma cells.
  • Adoptive transfer of B/I-activated T cells grown in IL-7 + IL-15 or the alternating regimen had equal or greater efficacy on a "per-cell" basis against melanoma metastases.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):320-6 [17433869.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2018-27 [17277105.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2984-92 [18413768.001]
  • [Cites] Immunol Cell Biol. 2008 May-Jun;86(4):312-9 [18362947.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2698-703 [18565862.001]
  • [Cites] Immunity. 2001 Feb;14(2):105-10 [11239443.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4511-7 [11591778.001]
  • [Cites] Crit Rev Immunol. 2001;21(1-3):215-48 [11642606.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1075-86 [11844833.001]
  • [Cites] Expert Opin Biol Ther. 2002 Mar;2(3):237-47 [11890864.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4980-7 [11994449.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Clin Immunol. 2003 Jan;106(1):5-9 [12584044.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):884-90 [12610189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3392-7 [12626740.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):355-60 [12640450.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):666-75 [12951585.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2003;51(4):245-57 [12956434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7315-23 [15187107.001]
  • [Cites] Int Immunol. 2004 Sep;16(9):1283-94 [15262898.001]
  • [Cites] J Immunol. 1989 Aug 15;143(4):1283-9 [2545785.001]
  • [Cites] J Immunol. 1989 Nov 1;143(9):2887-93 [2530282.001]
  • [Cites] Cancer Immunol Immunother. 1990;32(4):245-50 [2175673.001]
  • [Cites] J Immunol. 1991 Jun 15;146(12):4414-20 [1674958.001]
  • [Cites] J Immunol. 1991 Jul 15;147(2):729-37 [1830072.001]
  • [Cites] J Surg Res. 1992 Jun;52(6):543-8 [1528028.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):833-9 [8428364.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1380-7 [8443817.001]
  • [Cites] Mol Pharmacol. 1994 Aug;46(2):374-9 [8078499.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):53-8 [7834429.001]
  • [Cites] Immunology. 1996 Mar;87(3):447-53 [8778032.001]
  • [Cites] Annu Rev Immunol. 1996;14:259-74 [8717515.001]
  • [Cites] Ann Surg Oncol. 1997 Jun;4(4):334-41 [9181234.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4330-6 [9574536.001]
  • [Cites] Immunity. 1998 May;8(5):615-23 [9620682.001]
  • [Cites] Cancer Immunol Immunother. 1999 May-Jun;48(2-3):139-46 [10414468.001]
  • [Cites] Immunity. 1999 Sep;11(3):281-8 [10514006.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8062-7 [15520217.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):331-7 [15785758.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1177-87 [15841203.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):326-32 [15886125.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1142-51 [16227984.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):284-93 [16699371.001]
  • [Cites] Hum Immunol. 2006 Jun;67(6):469-77 [16728271.001]
  • [Cites] Nat Rev Immunol. 2006 Aug;6(8):595-601 [16868550.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5060-9 [17075125.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1309-15 [18209024.001]
  • (PMID = 19198835.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016059
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Bryostatins; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Interleukin-7; 0 / Interleukins; 0 / RNA, Messenger; 37O2X55Y9E / bryostatin 1; 56092-81-0 / Ionomycin; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS581989; NLM/ PMC4037402
  •  go-up   go-down


27. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, Galeotti T: Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene; 2006 Jun 22;25(26):3689-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of the c-Met/hepatocyte growth factor receptor(HGF-R) proto-oncogene and abnormal generation of intracellular oxygen species (reactive oxygen species (ROS)) have been linked, by independent lines of evidence, to cell transformation and to malignant growth.
  • By comparing two subpopulations of the B16 mouse melanoma (B16-F0 and B16-F10) endowed with different lung metastasis capacities (low and high, respectively) we found that both the expression/phosphorylation of c-Met and the steady-state levels of ROS positively correlated with metastatic growth. shRNA-mediated downregulation of c-Met in F10 cells led to a parallel decrease in the generation of oxygen species and in metastatic capacity, suggesting that oxidants may mediate the pro-metastatic activity of the HGF receptor. c-Met activation by a ligand elicits the formation of oxidant species through the oxidase-coupled small GTPase Rac-1, a relevant downstream target of the HGF-R.
  • [MeSH-minor] Animals. Free Radical Scavengers / pharmacology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness. Organometallic Compounds / pharmacology. Oxidation-Reduction. Phosphorylation. Salicylates / pharmacology. Superoxides / metabolism. rac1 GTP-Binding Protein


28. Curran MA, Allison JP: Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res; 2009 Oct 1;69(19):7747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations and aberrations in gene expression.
  • Previously, we have shown that combining blockade of the T-cell-negative costimulatory molecule CTL-associated antigen 4 (CTLA-4) and vaccination with irradiated B16 tumor expressing granulocyte macrophage colony-stimulating factor (GM-CSF;.
  • Gvax) promotes rejection of established murine melanomas.
  • Here we show that, like GM-CSF, the cytokine Flt3 ligand (Flt3L) expressed in B16 and coupled with CTLA-4 blockade promotes both prophylactic and therapeutic rejection of B16.
  • When administered at the site of growing tumor, Gvax fails to prevent tumor outgrowth in any mice, whereas the B16-Flt3L vaccine (Fl3vax) induces the rejection of 75% of melanomas implanted 3 days before vaccination.
  • Gvax and Fl3vax did not synergize when used in combination in treating B16 melanoma even in the context of CD25+ regulatory T-cell depletion.
  • Further, we show that a combination of Flt3L expression and CTLA-4 blockade can also promote the rejection of established TRAMP prostate adenocarcinomas, proving that the utility of this treatment extends beyond melanoma.
  • Engineering Flt3L to be constitutively secreted and attaching an IgG2a tail yielded a B16 vaccine that, when combined with CTLA-4 blockade, prevented the outgrowth of significantly more 5-day implanted B16-BL6 tumors than did Gvax.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Apr 1;164(7):3581-90 [10725713.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7577-84 [18025203.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3239-46 [10866317.001]
  • [Cites] J Exp Med. 2001 Aug 20;194(4):481-9 [11514604.001]
  • [Cites] Cytokine. 2002 Feb 7;17(3):119-30 [11895330.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):185-93 [11900993.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):953-8 [11927638.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(12):979-86 [12098066.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):486-9 [12496473.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3188-92 [12789295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Exp Med. 1992 Jul 1;176(1):59-65 [1613466.001]
  • [Cites] Curr Opin Immunol. 1992 Oct;4(5):619-23 [1418729.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1057-65 [8350046.001]
  • [Cites] FASEB J. 1994 Oct;8(13):1055-60 [7926371.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3233-6 [7805752.001]
  • [Cites] J Exp Med. 1995 Jul 1;182(1):219-31 [7790818.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3292-5 [7561021.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] Immunity. 1996 Apr;4(4):349-55 [8612129.001]
  • [Cites] Hum Gene Ther. 1996 Aug 1;7(12):1405-13 [8844199.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):1953-62 [8920882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103 [9223321.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4036-41 [9307290.001]
  • [Cites] J Immunol. 1998 Jul 1;161(1):342-6 [9647242.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):37-48 [9720755.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):338-44 [15785759.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):343-51 [16000952.001]
  • [Cites] Cell Res. 2006 Feb;16(2):126-33 [16474424.001]
  • [Cites] Curr Opin Immunol. 2006 Apr;18(2):206-13 [16464564.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4895-903 [16651446.001]
  • [Cites] Immunology. 2006 Jun;118(2):240-9 [16771859.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1364-71 [17154174.001]
  • [Cites] Clin Immunol. 2007 May;123(2):176-89 [17276735.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1902-13 [17557120.001]
  • [Cites] Cancer Gene Ther. 2007 Aug;14(8):696-705 [17514193.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:253-61 [17360795.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3827-32 [17766680.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2444-8 [10811122.001]
  • (PMID = 19738077.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057986-10; United States / NCI NIH HHS / CA / R01 CA057986-10
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / Cancer Vaccines; 0 / Ctla4 protein, mouse; 0 / Membrane Proteins; 0 / flt3 ligand protein; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.4.17.1 / Carboxypeptidases A; EC 3.4.17.1 / Cpa3 protein, mouse
  • [Other-IDs] NLM/ NIHMS140233; NLM/ PMC2756314
  •  go-up   go-down


29. Zeng SG, Zhang JR, Zhang JC, Wu SQ, Liu QC, Ai WJ, Xue GC: [Construction of the eukaryotic coexpression vector containing Mycobacterium tuberculosis heat shock protein 70 and green fluorescent protein]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):433-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recombinant plasmid was transfected into mouse melanoma B16 cell line, and the green fluorescent cells were detected by fluorescence microscopy and mtHSP70 expression was detected by Western blotting.
  • The transfected mouse melanoma B16 cells exhibited green fluorescence under fluorescence microscopy and expressed mtHSP70 protein as demonstrated by Western blotting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304518.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / HSP70 Heat-Shock Proteins; 0 / Recombinant Fusion Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


30. Molavi O, Ma Z, Hamdy S, Lavasanifar A, Samuel J: Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124. Immunopharmacol Immunotoxicol; 2009 Jun;31(2):214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition the immunomodulatory and anticancer effects of 7-acyl lipid A PLGA-NPs in combination with a STAT3 inhibitory agent, JSI-124, in a B16 mouse melanoma model was explored, in vivo.
  • Besides, daily Intra-tumoral co-administration of 7-acyl lipid A PLGA-NPs and JSI-124 in C57BL/6 mice bearing B16-F10 tumor for 8 days resulted in a significant increase in the percentage of tumor infiltrated T cells as compared with control group that received PBS and monotherapy groups.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Delivery Systems. Immune Tolerance / drug effects. Lipid A / analogs & derivatives. Melanoma, Experimental / drug therapy. STAT3 Transcription Factor / antagonists & inhibitors. Triterpenes / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798092.001).
  • [ISSN] 1532-2513
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 42407
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Glycolates; 0 / Lipid A; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, mouse; 0 / Triterpenes; 0 / polylactic acid-polyglycolic acid copolymer; 2222-07-3 / cucurbitacin I; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


31. Kim YJ, No JK, Lee JH, Chung HY: 4,4'-Dihydroxybiphenyl as a new potent tyrosinase inhibitor. Biol Pharm Bull; 2005 Feb;28(2):323-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to tyrosinase inhibiting activity, melanin biosynthesis was assessed in B16F10 melanoma cells (B16 cells).
  • [MeSH-minor] Cell Survival / drug effects. Cell Survival / physiology. Dose-Response Relationship, Drug. Enzyme Inhibitors / chemistry. Enzyme Inhibitors / pharmacology. Humans. Melanoma, Experimental / enzymology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684492.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biphenyl Compounds; 0 / Enzyme Inhibitors; EC 1.14.18.1 / Monophenol Monooxygenase; R8994A0904 / 4,4'-dihydroxybiphenyl
  •  go-up   go-down


32. Li W, Takahashi M, Shibukawa Y, Yokoe S, Gu J, Miyoshi E, Honke K, Ikeda Y, Taniguchi N: Introduction of bisecting GlcNAc in N-glycans of adenylyl cyclase III enhances its activity. Glycobiology; 2007 Jun;17(6):655-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established GnT-III stable expressing cell lines of Neuro-2a mouse neuroblastoma cells and B16 mouse melanoma cells.
  • Since endogenous AC expression levels in Neuro-2a and B16 cells were too low to permit the glycosylation status to be examined, AC type III (ACIII) was overexpressed in a stable expression system using Flp-In-293 cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324955.001).
  • [ISSN] 0959-6658
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Polysaccharides; 1F7A44V6OU / Colforsin; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.144 / beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase; EC 4.6.1.1 / Adenylyl Cyclases; EC 4.6.1.1 / adenylate cyclase 3; V956696549 / Acetylglucosamine
  •  go-up   go-down


33. Gu Q, Xu JY, Cheng LG, Xia WJ: [The effect of Angelica sinensis on adhesion, invasion, migration and metastasis of melanoma cells]. Zhong Yao Cai; 2007 Mar;30(3):302-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effect of Angelica sinensis on adhesion, invasion, migration and metastasis of melanoma cells].
  • OBJECTIVE: To study the effect of Angelica sinensis on invasion, adhesion, migration and metastasis of B16-BL6 metastatic mouse melanoma cells and discuss its functional mechanism.
  • METHODS: The proliferation, adhesion, invasion and migration capacity of B16-BL6 metastatic cells was evaluated by MTT assay, adhesion assay and reconstituted basement membrane invasion and migration assay in vitro respectively.
  • Mouse spontaneous melanoma model was used to study the effect of Angelica sinensis on metastasis in vivo.
  • RESULTS: The extract of Angelica sinensis inhibited the proliferation of B16-BL6 metastatic cells and its migration capacity significantly.
  • It regulated bidirectionally the adhesion of B16-BL6 metastatic cells to the basement component laminin while it had no effect on the invasion capacity.
  • In the mouse spotaneous melanoma model, the lung metastatic nodes number and its volume were significantly decreased after continuously treated with the extract of Angelica sinensis at the concentration of 3.67 mg/kg.
  • CONCLUSION: The extract of Angelica sinensis can inhibit the metastasis of of B16-BL6 metastatic mouse melanoma cells and its mechanism is maybe that Angelica sinensis can inhibit the B16-BL6 cells adhering to the ECM and reduce the migration of B16-BL6 cells.
  • [MeSH-major] Angelica sinensis / chemistry. Cell Movement / drug effects. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634038.001).
  • [ISSN] 1001-4454
  • [Journal-full-title] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
  • [ISO-abbreviation] Zhong Yao Cai
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Laminin
  •  go-up   go-down


34. Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M: Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother; 2007 Sep;56(9):1417-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated mice bearing established subcutaneous B16 melanomas or RenCa renal cell carcinomas with intraperitoneal (i.p.) or subcutaneous (s.c.
  • Whereas both routes of IL-21 administration significantly inhibited growth of small, established RenCa and B16 tumors, only s.c. therapy significantly inhibited the growth of large, established tumors.
  • In accordance, both routes of IL-21 administration significantly increased the density of tumor infiltrating CD8(+) T cells in both B16 and RenCa tumors; and in the RenCa model s.c. administration of IL-21 led to a significantly higher density of tumor infiltrating CD8(+) T cells compared to i.p. administration.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Carcinoma, Renal Cell / therapy. Interleukins / therapeutic use. Kidney Neoplasms / therapy. Lymphocytes, Tumor-Infiltrating / immunology. Melanoma, Experimental / therapy. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285290.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukins; 0 / interleukin-21
  •  go-up   go-down


35. Nemethova M, Auinger S, Small JV: Building the actin cytoskeleton: filopodia contribute to the construction of contractile bundles in the lamella. J Cell Biol; 2008 Mar 24;180(6):1233-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparable results were obtained with B16 melanoma cells.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Muscle Res Cell Motil. 1980 Jun;1(2):127-46 [6894451.001]
  • [Cites] Dev Biol. 1981 Jul 15;85(1):113-22 [7018957.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1982;46 Pt 2:599-611 [6955102.001]
  • [Cites] J Cell Biol. 1983 Oct;97(4):1207-13 [6684662.001]
  • [Cites] Nature. 1984 Jul 5-11;310(5972):58-61 [6377086.001]
  • [Cites] J Cell Biol. 1984 Oct;99(4 Pt 1):1478-85 [6541223.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):517-23 [16099152.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4473-84 [16014609.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):18-25 [16337369.001]
  • [Cites] Nat Cell Biol. 2006 Mar;8(3):215-26 [16501565.001]
  • [Cites] J Cell Biol. 1985 Aug;101(2):597-602 [4040521.001]
  • [Cites] J Neurosci. 1985 Dec;5(12):3204-13 [4078625.001]
  • [Cites] Nature. 1986 Oct 23-29;323(6090):712-5 [3773996.001]
  • [Cites] J Cell Biol. 1987 Dec;105(6 Pt 1):2803-9 [3121637.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):747-60 [3126193.001]
  • [Cites] Methods Cell Biol. 2008;88:257-72 [18617038.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):321-2 [10559946.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):136-43 [10559899.001]
  • [Cites] Trends Cell Biol. 2002 Mar;12(3):112-20 [11859023.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jul;34(7):726-30 [11950590.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jul;34(7):746-61 [11950592.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] Neuron. 1993 Aug;11(2):237-51 [8352941.001]
  • [Cites] Symp Soc Exp Biol. 1993;47:35-56 [8165576.001]
  • [Cites] Cell. 1995 Apr 7;81(1):53-62 [7536630.001]
  • [Cites] J Cell Biol. 1995 Jun;129(5):1275-86 [7775574.001]
  • [Cites] J Cell Sci. 1995 May;108 ( Pt 5):1977-90 [7657718.001]
  • [Cites] J Cell Biol. 1995 Nov;131(4):989-1002 [7490299.001]
  • [Cites] J Cell Biol. 1996 Jun;133(6):1403-15 [8682874.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):913-26 [9265656.001]
  • [Cites] J Cell Biol. 1997 Nov 3;139(3):797-807 [9348295.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] J Cell Sci. 1998 Jun;111 ( Pt 12):1649-58 [9601095.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;40(1):59-70 [9605972.001]
  • [Cites] Biochim Biophys Acta. 1998 Sep 16;1404(3):271-81 [9739149.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1245-58 [10087267.001]
  • [Cites] Curr Biol. 1999 Jun 17;9(12):640-8 [10375527.001]
  • [Cites] J Exp Zool. 1959 Oct-Dec;142:5-73 [13711840.001]
  • [Cites] Biochemistry. 2005 Jan 18;44(2):584-8 [15641783.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):129-33 [15668168.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):619-25 [15908944.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):165-73 [16360240.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):383-94 [16651381.001]
  • [Cites] FEBS Lett. 2006 May 29;580(13):3223-8 [16697374.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2581-91 [16597702.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):863-75 [16966425.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):579-91 [17398099.001]
  • [Cites] Trends Cell Biol. 2007 Apr;17(4):178-86 [17320396.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2007;36:451-77 [17477841.001]
  • [Cites] Cytobiologie. 1978 Feb;16(2):308-25 [17621694.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):306-13 [18278037.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):9-19 [12110163.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):409-21 [12566431.001]
  • [Cites] Science. 2003 Apr 4;300(5616):142-5 [12677069.001]
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1163-77 [12810700.001]
  • [Cites] J Cell Sci. 2003 Nov 15;116(Pt 22):4605-13 [14576354.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1045-55 [14657236.001]
  • [Cites] J Cell Biol. 2004 Apr 26;165(2):233-42 [15117967.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Jul;58(3):143-59 [15146534.001]
  • [Cites] Mol Biol Cell. 2004 Jul;15(7):3497-508 [15133124.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3531-8 [15226373.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Nature. 1969 May 17;222(5194):641-4 [5768273.001]
  • [Cites] Exp Cell Res. 1970 Mar;59(3):393-8 [4907703.001]
  • [Cites] Exp Cell Res. 1970 Jun;60(3):437-44 [5463639.001]
  • [Cites] Ciba Found Symp. 1973;14:53-82 [4130535.001]
  • [Cites] Nature. 1978 Apr 13;272(5654):638-9 [565473.001]
  • [Cites] Exp Cell Res. 1979 May;120(2):335-48 [374104.001]
  • [Cites] Cell. 1979 Jun;17(2):285-93 [378407.001]
  • [Cites] Biochimie. 1981 Apr;63(4):307-23 [7013832.001]
  • (PMID = 18362182.001).
  • [ISSN] 1540-8140
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / Paxillin; 146808-54-0 / fascin; EC 3.6.1.- / Myosin Type II
  • [Other-IDs] NLM/ PMC2290848
  •  go-up   go-down


36. Kim YJ, Kang KS, Yokozawa T: The anti-melanogenic effect of pycnogenol by its anti-oxidative actions. Food Chem Toxicol; 2008 Jul;46(7):2466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work, utilizing cultured B16 melanoma cells (B16 cells), pycnogenol was investigated for its ability to inhibit tyrosinase activity and melanin biosynthesis.
  • Further, our results showed that through its anti-oxidative properties, pycnogenol suppressed .O2) NO., ONOO-, and .OH in in vitro assays, and reactive species, ONOO-, .O2, and NO., while up-regulating the reduced glutathione/oxidized glutathione ratio in B16 cells.
  • [MeSH-major] Flavonoids / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / enzymology. Monophenol Monooxygenase / antagonists & inhibitors. Oxidative Stress / drug effects. Peptides / pharmacology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482785.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Melanins; 0 / Peptides; 0 / pycnogenols; 11062-77-4 / Superoxides; 14691-52-2 / Peroxynitrous Acid; 31C4KY9ESH / Nitric Oxide; 3352-57-6 / Hydroxyl Radical; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


37. Chen PF, Liu LM, Chen Z, Lin SY, Song WX, Xu YF: [Effects of ethanol extracts of Panax notoginseng on liver metastasis of B16 melanoma grafted in mice]. Zhong Xi Yi Jie He Xue Bao; 2006 Sep;4(5):500-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of ethanol extracts of Panax notoginseng on liver metastasis of B16 melanoma grafted in mice].
  • OBJECTIVE: To observe the effects of ethanol extracts of Panax notoginseng on the tumor and the liver metastasis in experimental mice grafted with B16 melanoma.
  • METHODS: B16 melanoma was transplanted in the spleen of C57BL/6 mice.
  • [MeSH-major] Liver Neoplasms / prevention & control. Melanoma, Experimental / pathology. Panax notoginseng / chemistry. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965745.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Interferon-alpha; 0 / Plant Extracts; 3K9958V90M / Ethanol
  •  go-up   go-down


38. Farina HG, Pomies M, Alonso DF, Gomez DE: Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep; 2006 Oct;16(4):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer.
  • We have investigated the antitumor and antiangiogenic properties of soy isoflavone genistein in B16 melanoma and F3II mammary carcinoma mouse models.
  • Genistein inhibited uPA secreted by F3II cell monolayers, while inducing an increase in the proteolytic activity of B16 cells.
  • In vivo, i.p. administration of genistein at a dose of 10 mg/kg/day reduced tumor-induced angiogenesis in syngeneic mice implanted with B16 or F3II cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Genistein / pharmacology. Isoflavones / therapeutic use. Mammary Neoplasms, Animal / drug therapy. Melanoma / drug therapy. Soybeans / chemistry
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Animals. Culture Media, Conditioned / metabolism. Disease Models, Animal. Humans. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969510.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Culture Media, Conditioned; 0 / Isoflavones; DH2M523P0H / Genistein
  •  go-up   go-down


39. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM: Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol; 2008 Mar 1;180(5):3132-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B16/OVA melanoma cells were implanted into C57BL/6 (wild-type (WT)) and IFN-gamma-deficient (IFN-gamma-/-) mice.
  • The role of IFN-gamma signaling in tumor cells on class I expression was tested using B16/OVA cells engineered to overexpress a dominant negative mutant IFN-gamma receptor (B16/OVA/DNM).
  • Following implantation and treatment, expression of surface class I on tumor cells in vivo was increased in B16/OVA, but not in B16/OVA/DNM tumors, suggesting IFN-gamma acts directly on tumor cells to induce class I up-regulation.
  • [MeSH-major] Gamma Rays. Interferon-gamma / biosynthesis. Interferon-gamma / radiation effects. Melanoma, Experimental / immunology. Melanoma, Experimental / prevention & control

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292536.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI07285; United States / NCI NIH HHS / CA / CA28332
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


40. Fleischmann WR Jr, Wu TG: Development of an interferon-based cancer vaccine protocol: application to several types of murine cancers. Methods Mol Med; 2005;116:151-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This protocol has been used to develop cancer vaccines in mice against B16 melanoma, RM-1 prostate cancer, and P388 lymphocytic leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000860.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interferon-alpha
  •  go-up   go-down


41. van Deventer HW, O'Connor W Jr, Brickey WJ, Aris RM, Ting JP, Serody JS: C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res; 2005 Apr 15;65(8):3374-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung metastases were counted in wild-type (WT) and CCR5(-/-) mice following the injection of 1 x 10(6) B16-F10 melanoma cells.
  • [MeSH-major] Lung Neoplasms / secondary. Melanoma, Experimental / secondary. Receptors, CCR5 / physiology


42. Critchley-Thorne RJ, Stagg AJ, Vassaux G: Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. Mol Ther; 2006 Aug;14(2):183-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral administration of invasive E. coli coexpressing the model antigen ovalbumin and LLO from Listeria monocytogenes was able to elicit systemic protection against a lethal challenge of B16 tumor cells expressing ovalbumin.
  • [MeSH-major] Adhesins, Bacterial / genetics. Cancer Vaccines / therapeutic use. Escherichia coli / physiology. Immunotherapy, Active / methods. Melanoma, Experimental / therapy. Peyer's Patches / microbiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16581299.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Antigens, CD29; 0 / Antigens, Neoplasm; 0 / Bacterial Toxins; 0 / Cancer Vaccines; 0 / Heat-Shock Proteins; 0 / Hemolysin Proteins; 114073-91-5 / invasin, Yersinia; 72270-41-8 / hlyA protein, Listeria monocytogenes
  •  go-up   go-down


43. Kato Y, Ozawa S, Tsukuda M, Kubota E, Miyazaki K, St-Pierre Y, Hata R: Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J; 2007 Jun;274(12):3171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma.
  • Here, we show that acidic extracellular pH signaling involves both pathways of phospholipase D triggered by Ca2+ influx and acidic sphingomyelinase in mouse B16 melanoma cells.
  • [MeSH-major] Calcium / metabolism. Extracellular Fluid / chemistry. Matrix Metalloproteinase 9 / biosynthesis. Melanoma / enzymology. Phospholipase D / metabolism. Sphingomyelin Phosphodiesterase / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DESIPRAMINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540003.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Calcium Channels; 0 / Chelating Agents; 0 / Indolizines; 0 / NF-kappa B; 0 / Phenethylamines; 114432-13-2 / fantofarone; 139890-68-9 / 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; 27B90X776A / Mibefradil; 526U7A2651 / Egtazic Acid; 57WA9QZ5WH / Nimodipine; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase; EC 3.1.4.4 / Phospholipase D; EC 3.4.24.35 / Matrix Metalloproteinase 9; KU65374X44 / Perhexiline; SY7Q814VUP / Calcium; TG537D343B / Desipramine
  •  go-up   go-down


44. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R: ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther; 2010 Feb;9(2):379-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124460.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP10 protein, human; 0 / Bmp10 protein, mouse; 0 / Bone Morphogenetic Proteins; 0 / Growth Differentiation Factor 2; 0 / Immunoglobulin Fc Fragments; 0 / Recombinant Fusion Proteins; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / ALK1-Fc fusion protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


45. Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ, Henschler R, Breier G: Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer; 2007 May 1;120(9):1899-908
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation.
  • Metastasis continues to be the major cause of morbidity and mortality in malignant melanoma.
  • In our study, we explored whether inhibition of VEGFR-1 or VEGFR-2 signaling conveys distinct suppressive effects on B16 melanoma subcutaneous growth and metastasis formation.
  • The inhibition of VEGFR-1 or -2 alone had no significant influence on both melanoma growth and metastasis formation.
  • In contrast, simultaneous blockade of VEGFR-1 and -2 signaling strongly suppressed progression in both B16 tumor models.
  • There was no expression of VEGFR-1 or -2 detectable on the B16 cells used, excluding the melanoma cells as direct therapeutic targets.
  • Analyzing the contribution of progenitor-like cells during melanoma metastasis formation, we observed an enhanced proliferation and mobilization of VEGFR-1+ myeloid and VEGFR-2+ endothelial cells with progenitor potential by the induction of melanoma lung metastasis, which was not influenced by interference with VEGFR signaling.
  • However, the formation of lung metastasis was not affected, indicating that inhibition of the inflammatory response was not sufficient to efficiently block B16 melanoma metastasis development.
  • Taken together, our data suggest that in the utilized B16 tumor models the blockade of both the inflammatory and the VEGFR-2-dependent angiogenic response are necessary to effectively inhibit solid tumor growth and formation of lung metastasis by B16 melanoma cells.
  • [MeSH-major] Melanoma, Experimental / therapy. Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17230507.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


46. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL: Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res; 2009 Nov 1;69(21):8516-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We developed a recombinant oncolytic vaccinia virus expressing the 4-1BBL T-cell costimulatory molecule (rV-4-1BBL) and showed modest tumor regression in the poorly immunogenic B16 murine melanoma model.
  • These data suggest that vaccination with rV-4-1BBL in the setting of host nonmyeloablative lymphodepletion represents a logical strategy for improving oncolytic vaccination in melanoma, and perhaps other cancers as well.
  • [MeSH-major] 4-1BB Ligand / metabolism. Cancer Vaccines / therapeutic use. Lymphocyte Depletion. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Oncolytic Virotherapy. Vaccinia virus / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843856.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antibodies, Viral; 0 / Cancer Vaccines
  •  go-up   go-down


47. Sochanik A, Mitrus I, Smolarczyk R, Cichoń T, Snietura M, Czaja M, Szala S: Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Arch Immunol Ther Exp (Warsz); 2010 Jun;58(3):235-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The B16-F10 melanoma cell line was used for confirming, by flow cytometry and confocal microscopy, doxorubicin intracellular transfer as well as to induce experimental tumors in C57BL/6 mice.
  • Treatment of C57BL/6 mice bearing B16-F10 experimental tumors with a combination of vascular-disruptive peptide and doxorubicin-carrying pegylated liposomes (either passively targeted liposomes (PTL) or folate receptor targeted) gave better therapeutic effects when tumor development was re-challenged with a second cycle of combined therapy.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Doxorubicin / pharmacology. Drug Carriers. Epithelial Cells / drug effects. Liposomes. Melanoma, Experimental / drug therapy. Neovascularization, Pathologic. Peptide Fragments / pharmacology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20383751.001).
  • [ISSN] 1661-4917
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Carrier Proteins; 0 / Drug Carriers; 0 / Folate Receptors, GPI-Anchored; 0 / Integrin alphaVbeta3; 0 / Liposomes; 0 / Peptide Fragments; 0 / Receptors, Cell Surface; 80168379AG / Doxorubicin
  •  go-up   go-down


48. Culp WD, Neal R, Massey R, Egevad L, Pisa P, Garland D: Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res; 2006 Jun;5(6):1332-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model.
  • The B16-F10 mouse model of melanoma is a widely used model to study many aspects of cancer biology and therapeutics in a solid tumor.
  • Melanomas aggressively progress within a dynamic microenvironment containing in addition to tumor cells, stroma cells and components such as fibroblasts, immune cells, vascular cells, extracellular matrix (ECM) and extracellular molecules.
  • A comparative proteome analysis was performed on B16-F10 derived tumors in C57BL/6 mice at days 3, 5, 7, and 10.
  • This work illustrates changes in the biology of the B16-F10 tumor mass during tumor progression.
  • [MeSH-major] Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Proteome Res. 2006 Jun;5(6):1296 [16791990.001]
  • (PMID = 16739985.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


49. Arung ET, Yoshikawa K, Shimizu K, Kondo R: Isoprenoid-substituted flavonoids from wood of Artocarpus heterophyllus on B16 melanoma cells: cytotoxicity and structural criteria. Fitoterapia; 2010 Mar;81(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoprenoid-substituted flavonoids from wood of Artocarpus heterophyllus on B16 melanoma cells: cytotoxicity and structural criteria.
  • A structure-activity investigation of the effect of these isolated compounds (1-9) and structurally related compounds on B16 melanoma cells indicated that isoprenoid moiety substitutions in flavonoids enhance their cytotoxicity, and that the position of attachment and the number of isoprenoid-substituent moieties per molecule influence flavonoid cytotoxicity.
  • [MeSH-major] Artocarpus / chemistry. Flavonoids / pharmacology. Melanoma, Experimental / drug therapy. Plant Extracts / pharmacology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19686821.001).
  • [ISSN] 1873-6971
  • [Journal-full-title] Fitoterapia
  • [ISO-abbreviation] Fitoterapia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts; 0 / Terpenes
  •  go-up   go-down


50. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D: Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation; 2006 Oct 27;82(8):1060-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The murine MSC line C3H10T1/2 was coinjected with the Renca adenocarcinoma or the B16 melanoma cell lines in BALB/c mice.
  • RESULTS: The injection of MSC permitted the growth of the allogeneic B16 tumor cells and reduced the delay of tumor appearance when Renca cells were implanted, without modifying the kinetics of tumor growth.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Immunosuppression. Kinetics. Lung Neoplasms / secondary. Melanoma, Experimental. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Neoplasm Metastasis. Neoplasm Transplantation. Stem Cells / cytology. Transplantation, Isogeneic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060855.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Choi MY, Song HS, Hur HS, Sim SS: Whitening activity of luteolin related to the inhibition of cAMP pathway in alpha-MSH-stimulated B16 melanoma cells. Arch Pharm Res; 2008 Sep;31(9):1166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whitening activity of luteolin related to the inhibition of cAMP pathway in alpha-MSH-stimulated B16 melanoma cells.
  • To examine the possibility of luteolin as a whitening agent, we measured antioxidant activity using DPPH assay, NBT/XO assay and intracellular ROS scavengning assay and depigmenting activity using tyrosinase assay, alpha-MSH-induced melanin production in B-16 cells.
  • Although luteolin did not directly inhibit tyrosinase activity, it dose-dependently inhibited both tyrosinase activity and melanin production in B16 melanoma cells stimulated by 1 microM alpha-MSH.
  • Luteolin dose-dependently inhibited cAMP levels in B16 melanoma cells stimulated by 1 microM alpha-MSH and 1 microM forskolin, which suggest that luteolin directly inhibits adenyl cyclase in B16 melanoma cells.
  • Therefore, these results suggest that whitening activity of luteolin may be due to the inhibition of adenyl cyclase involved in the signal pathway of alpha-MSH in B16 melanoma cells.
  • [MeSH-major] Cyclic AMP / physiology. Luteolin / pharmacology. Melanins / antagonists & inhibitors. Melanoma, Experimental / metabolism. Monophenol Monooxygenase / antagonists & inhibitors. Signal Transduction / drug effects. alpha-MSH / pharmacology

  • Hazardous Substances Data Bank. ARBUTIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806960.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biphenyl Compounds; 0 / Free Radical Scavengers; 0 / Melanins; 0 / Picrates; 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 1F7A44V6OU / Colforsin; 581-05-5 / alpha-MSH; C5INA23HXF / Arbutin; E0399OZS9N / Cyclic AMP; EC 1.14.18.1 / Monophenol Monooxygenase; EC 1.17.3.2 / Xanthine Oxidase; KUX1ZNC9J2 / Luteolin
  •  go-up   go-down


52. Labarthe MC, Halanek N, Birchall L, Russell N, Desel C, Todryk S, Peters MJ, Lucas A, Falkenberg FW, Dalgleish AG, Whelan M, Ward SJ: The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother; 2006 Mar;55(3):277-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
  • To address this, weakly immunogenic B16-F10 (H-2b) murine melanoma was transfected to secrete either GM-CSF, IL-4 or IL-7.
  • Allogeneic B16-F10 cells and syngeneic K1735 cells generated CTL against K1735 suggesting cross-reactive immunity.
  • [MeSH-major] Cancer Vaccines / radiation effects. Cytokines / secretion. Melanoma, Experimental / prevention & control. Transplantation, Homologous / immunology. Transplantation, Isogeneic / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158275.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines
  •  go-up   go-down


53. Roullier C, Chollet-Krugler M, Weghe Pv, Devehat FL, Boustie J: A novel aryl-hydrazide from the marine lichen Lichina pygmaea: isolation, synthesis of derivatives, and cytotoxicity assays. Bioorg Med Chem Lett; 2010 Aug 1;20(15):4582-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, the cytotoxicity of the ortho-, meta-, and para-hydroxyl isomers along with their respective benzyl intermediates, and a natural methoxylated analog, were evaluated on murine and human melanoma cells (B16, A375).
  • The para-hydroxyl isomer 6 was found to be the most active (IC(50)=1.6 microM) on B16 cells.
  • [MeSH-minor] Animals. Benzyl Compounds / chemistry. Cell Line, Tumor. Glutamic Acid / chemistry. Humans. Isomerism. Magnetic Resonance Spectroscopy. Melanoma, Experimental / drug therapy. Mice. Molecular Conformation. Phenylhydrazines / chemistry

  • Hazardous Substances Data Bank. PHENYLHYDRAZINE .
  • Hazardous Substances Data Bank. HYDRAZINE SULFATE .
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. HYDRAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20570625.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzyl Compounds; 0 / Hydrazines; 0 / Phenylhydrazines; 0 / pygmeine; 064F424C9K / phenylhydrazine; 27RFH0GB4R / hydrazine; 3KX376GY7L / Glutamic Acid
  •  go-up   go-down


54. Kang JH, Asai D, Oishi J, Kawamura K, Toita R, Jiang Y, Mori T, Niidome T, Katayama Y: Role of plasma as activator and cofactor in phosphorylation catalyzed by protein kinase C. Cell Biochem Funct; 2008 Jan-Feb;26(1):70-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lysate samples were prepared from normal skin or melanoma tissue and were reacted with a PKC peptide substrate in the presence or absence of plasma.
  • In normal skin tissue lysates, the phosphorylation rates were much lower than those in melanoma tissue lysates.
  • However, the level of phosphorylated peptide was increased in both normal skin and melanoma tissue lysates if plasma was present.
  • Phosphorylation rates in the samples taken from the centre of B16 melanoma tissue were lower than those in samples taken from the edge.
  • [MeSH-minor] Animals. Catalysis. Enzyme Activation / physiology. Male. Melanoma, Experimental / enzymology. Mice. Peptides / chemical synthesis. Peptides / metabolism. Phosphorylation. Signal Transduction / physiology. Skin / enzymology. Substrate Specificity / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 John Wiley & Sons, Ltd.
  • (PMID = 17295388.001).
  • [ISSN] 1099-0844
  • [Journal-full-title] Cell biochemistry and function
  • [ISO-abbreviation] Cell Biochem. Funct.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coenzymes; 0 / Peptides; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


55. Seo WG, Hwang JC, Kang SK, Jin UH, Suh SJ, Moon SK, Kim CH: Suppressive effect of Zedoariae rhizoma on pulmonary metastasis of B16 melanoma cells. J Ethnopharmacol; 2005 Oct 3;101(1-3):249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressive effect of Zedoariae rhizoma on pulmonary metastasis of B16 melanoma cells.
  • The inhibitory effect of Curcuma zedoaria Roscoe (WE-CZ) on experimental pulmonary metastasis of B16 melanoma cells was investigated.
  • When the duration of WE-CZ intake was examined, survival time was not affected by pre-intake before B16 melanoma cell inoculation and was slightly extended by post-intake after B16 melanoma cell inoculation, although the life span was prolonged by intake throughout the experiment.
  • The elevated NO was found to serve as a cytotoxic mediator against B16 melanoma cells in co-culture with macrophages.
  • On the contrary, B16 melanoma-conditioned medium reduced NO production by macrophages.
  • These findings indicate that WE-CZ possesses anti-migratory effects on B16 melanoma cells and that the macrophage function-modulating activity by WE-CZ appears to underlie its anti-metastatic activity, which leads to a decrease in the number of lung metastatic surface nodules and the extension of life span.
  • [MeSH-major] Curcuma. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy. Phytotherapy. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023317.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


56. Tanaka Y, Koido S, Ohana M, Liu C, Gong J: Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol; 2005 Feb 1;174(3):1274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MHC class II- and MUC1-positive fusion cells were constructed by fusion of B16/MUC1 melanoma cells with IKO-DC (IKO/B16-FC).
  • One group of mice was immunized with 5 x 10(5) IKO/B16-FC and then challenged with B16/Ia(+)/MUC1 on one flank and MC38/MUC1 on the other flank.
  • Immunization of these mice with IKO/B16-FC resulted in 100 and 78.6% protection against B16/Ia(+)/MUC1 and MC38/MUC1 tumor challenge, respectively.
  • The antitumor immunity induced by immunization with IKO/B16-FC was able to inhibit the growth of MHC class II-negative tumor.
  • [MeSH-minor] Animals. Antigen Presentation / genetics. Antigen Presentation / immunology. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Cell Line, Tumor. Cells, Cultured. Histocompatibility Antigens Class I / administration & dosage. Histocompatibility Antigens Class I / biosynthesis. Interferon-gamma / antagonists & inhibitors. Lymphocyte Activation / genetics. Lymphocyte Activation / immunology. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. T-Lymphocytes / immunology. T-Lymphocytes / pathology. T-Lymphocytes, Cytotoxic / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661883.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA87057
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


57. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M: Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res; 2007 Nov 1;67(21):10519-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main goal of this work was to investigate the consequences of TLR4 activation present on tumor cells in two different animal models of cancer: the Dunning rat prostate cancer and the B16 murine melanoma models.
  • [MeSH-major] Melanoma, Experimental / prevention & control. Prostatic Neoplasms / prevention & control. Toll-Like Receptor 4 / immunology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974996.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Lipid A; 0 / Tlr4 protein, mouse; 0 / Tlr4 protein, rat; 0 / Toll-Like Receptor 4; 0 / Transcription Factor RelA
  •  go-up   go-down


58. Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B: Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother; 2007 Apr;56(4):459-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-tumor activities of adecatumumab and mu-adecatumumab were then compared side-by-side in a lung metastasis mouse model established with a syngeneic B16 melanoma line expressing human EpCAM at physiologically relevant levels.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937114.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FCGR1A protein, human; 0 / Fc gamma receptor IIA; 0 / MT201 antibody, human; 0 / Receptors, IgG
  •  go-up   go-down


59. Cho YH, Kim JH, Park SM, Lee BC, Pyo HB, Park HD: New cosmetic agents for skin whitening from Angelica dahurica. J Cosmet Sci; 2006 Jan-Feb;57(1):11-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To develop a new whitening agent for cosmetics from natural products, Angelica dahurica was selected for its inhibitory effect on melanogenesis in B16 melanoma cells.
  • They significantly inhibited tyrosinase synthesis in B16 melanoma cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. Furocoumarins / chemistry. Furocoumarins / isolation & purification. Gene Expression / drug effects. Humans. Melanins / antagonists & inhibitors. Melanins / biosynthesis. Melanoma, Experimental / drug therapy. Melanoma, Experimental / enzymology. Melanoma, Experimental / genetics. Melanoma, Experimental / metabolism. Mice. Monophenol Monooxygenase / antagonists & inhibitors. Monophenol Monooxygenase / biosynthesis. Monophenol Monooxygenase / genetics. Monophenol Monooxygenase / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • Hazardous Substances Data Bank. IMPERATORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676120.001).
  • [ISSN] 1525-7886
  • [Journal-full-title] Journal of cosmetic science
  • [ISO-abbreviation] J Cosmet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Furocoumarins; 0 / Melanins; 0 / Plant Extracts; 0 / RNA, Messenger; 482-45-1 / isoimperatorin; EC 1.14.18.1 / Monophenol Monooxygenase; K713N25C78 / imperatorin
  •  go-up   go-down


60. Kurosaki T, Kitahara T, Fumoto S, Nishida K, Yamamoto K, Nakagawa H, Kodama Y, Higuchi N, Nakamura T, Sasaki H: Chondroitin sulfate capsule system for efficient and secure gene delivery. J Pharm Pharm Sci; 2010;13(3):351-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those cationic complexes showed high transgene efficiency in B16-F10 cells; however, they also had high cytotoxicity and strong agglutination with erythrocytes.
  • The ternary complexes encapsulated by CS showed high transgene efficiency in B16-F10 cells with low cytotoxicity and agglutination.
  • [MeSH-minor] Animals. Arginine / analogs & derivatives. Cations. Cell Line, Tumor. Drug Delivery Systems. Erythrocytes / physiology. Gene Expression. Hemolysis. Liposomes. Lysine / analogs & derivatives. Melanoma, Experimental. Mice. Phosphatidylethanolamines. Plasmids. Quaternary Ammonium Compounds. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092708.001).
  • [ISSN] 1482-1826
  • [Journal-full-title] Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques
  • [ISO-abbreviation] J Pharm Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / 1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine; 0 / Cations; 0 / Liposomes; 0 / Phosphatidylethanolamines; 0 / Polyethylenes; 0 / Quaternary Ammonium Compounds; 104162-48-3 / N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium; 9007-28-7 / Chondroitin Sulfates; 94ZLA3W45F / Arginine; K3Z4F929H6 / Lysine
  •  go-up   go-down


61. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW: Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol; 2010 Apr 15;184(8):4215-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
  • In vitro generated OVA-specific IL-17-producing CD8 T effector cells (Tc17) from OT-1 mice, adoptively transferred into B16-OVA tumor-bearing mice, controlled tumor growth in early and late stage melanoma.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 1;164(9):4783-9 [10779785.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2294-303 [19644886.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6500-8 [11359800.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):424-34 [11418679.001]
  • [Cites] Oncology. 2001;61(1):79-89 [11474253.001]
  • [Cites] Immunology. 2002 Feb;105(2):231-43 [11872099.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2114-21 [11877287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2402-12 [12928387.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):406-14 [14729652.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1380-90 [14734713.001]
  • [Cites] Immunity. 2004 Feb;20(2):219-30 [14975243.001]
  • [Cites] Nat Med. 2004 Mar;10(3):294-8 [14981514.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1738-43 [15265903.001]
  • [Cites] J Exp Med. 1983 Oct 1;158(4):1356-61 [6413638.001]
  • [Cites] Science. 1984 Sep 28;225(4669):1487-9 [6332379.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):889-97 [3493432.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1043-50 [8439951.001]
  • [Cites] Nature. 1994 May 5;369(6475):31-7 [8164737.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1715-28 [7525836.001]
  • [Cites] Immunity. 1995 Mar;2(3):271-9 [7697544.001]
  • [Cites] Immunol Lett. 1995 Jan;44(1):35-40 [7721341.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5483-6 [7499828.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):796-807 [9053507.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3513-21 [9531313.001]
  • [Cites] Xenotransplantation. 1998 May;5(2):146-53 [9584828.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):541-51 [9646176.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27467-73 [9765276.001]
  • [Cites] J Immunol. 1999 Jan 1;162(1):577-84 [9886435.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1345-52 [10225978.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):249-57 [15657294.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1222-9 [16227989.001]
  • [Cites] Arthritis Res Ther. 2006;8(2):R50 [16507178.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8191-201 [17114496.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):281-6 [17433650.001]
  • [Cites] J Exp Med. 2007 May 14;204(5):995-1001 [17470641.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Cell Mol Immunol. 2007 Aug;4(4):277-85 [17764618.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3254-61 [18519750.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):1794-8 [19201830.001]
  • [Cites] J Immunol. 2009 Mar 15;182(6):3469-81 [19265125.001]
  • [Cites] J Immunol. 2009 Jul 1;183(1):560-7 [19542467.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):7116-24 [11120842.001]
  • (PMID = 20237297.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA071833-12; United States / NCI NIH HHS / CA / R01 CA071833; United States / NCI NIH HHS / CA / CA71833; United States / NCI NIH HHS / CA / R01 CA071833-12
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-17; 9006-59-1 / Ovalbumin
  • [Other-IDs] NLM/ NIHMS189043; NLM/ PMC2851479
  •  go-up   go-down


62. Zhang C, Lu Y, Tao L, Tao X, Su X, Wei D: Tyrosinase inhibitory effects and inhibition mechanisms of nobiletin and hesperidin from citrus peel crude extracts. J Enzyme Inhib Med Chem; 2007 Feb;22(1):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IC50 of nobiletin and hesperidin were 1.49 mM and 16.08 mM, respectively and their inhibition mechanisms are competitive type with inhibition constant (Ki) 2.82 mM and noncompetitive type with Ki 9.16 mM, respectively.
  • Their inhibition of melanogenesis in B16 mouse melanoma cells was also evaluated.
  • Nobiletin and PCPE gave efficacious antiproliferation effects on the B16 mouse melanoma cell with IC50 values 88.6 microM and 62.96 microg/mL, respectively, through the MTT test.
  • Hesperidin and other crude extracts showed very low cytotoxity to the B16 cell.
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Melanins / metabolism. Melanoma, Experimental / metabolism. Melanoma, Experimental / pathology. Mice. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373553.001).
  • [ISSN] 1475-6366
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Flavones; 0 / Melanins; 0 / Plant Extracts; D65ILJ7WLY / nobiletin; E750O06Y6O / Hesperidin; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


63. Riond J, Rodriguez S, Nicolau ML, al Saati T, Gairin JE: In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun; 2009;9:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, using the murine model of B16 melanoma, we demonstrate that the MHCI status of tumor cells in vivo is regulated by the microenvironment.
  • [MeSH-major] Histocompatibility Antigens Class I / immunology. Killer Cells, Natural / immunology. Melanoma / immunology. Melanoma / pathology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] Cancer Sci. 2009 Aug;100(8):1494-501 [19432881.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1095-9 [11221838.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Immunol Rev. 2002 Oct;188:9-21 [12445277.001]
  • [Cites] Eur J Immunol. 2003 Apr;33(4):850-60 [12672050.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):433-42 [12900519.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5940-7 [14634105.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):378-85 [14729648.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2651-60 [354778.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1495-8 [281556.001]
  • [Cites] Biochemistry. 1986 Jan 28;25(2):312-8 [2937447.001]
  • [Cites] Annu Rev Immunol. 1988;6:359-80 [3289570.001]
  • [Cites] J Immunol. 1990 Jul 1;145(1):380-6 [2113557.001]
  • [Cites] J Exp Med. 1993 Jan 1;177(1):201-5 [8418201.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4707-14 [8648116.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4846-54 [9144500.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):252-60 [15611247.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):679-84 [15703823.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3808-17 [15749922.001]
  • [Cites] Immunity. 2005 Mar;22(3):371-83 [15780993.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):722-9 [15951814.001]
  • [Cites] J Exp Med. 2005 Jul 18;202(2):203-7 [16027234.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):905-13 [16393975.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):25-31 [16417214.001]
  • [Cites] Nat Med. 2006 Feb;12(2):214-9 [16444265.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4331-6 [16547270.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1201-8 [16596236.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71 [16172907.001]
  • [Cites] Trends Immunol. 2006 Jun;27(6):282-90 [16698319.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):715-27 [16977338.001]
  • [Cites] Int Rev Cytol. 2007;256:139-89 [17241907.001]
  • [Cites] Gene Ther. 2007 May;14(9):752-9 [17344906.001]
  • [Cites] Cancer Immunol Immunother. 2007 Aug;56(8):1153-61 [17160409.001]
  • [Cites] Scand J Immunol. 2007 Oct;66(4):402-9 [17850584.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7459-68 [18094430.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):146-54 [18176566.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3627-35 [18322166.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3766-74 [18322182.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1279-86 [18422748.001]
  • [Cites] Cancer Immun. 2008;8:14 [18783178.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5904-12 [18836471.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):39-43 [19109132.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1594-604 [19089914.001]
  • [Cites] Bull Acad Natl Med. 2008 Oct;192(7):1469-87; discussion 1487-9 [19445369.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2665-70 [10946296.001]
  • (PMID = 19877577.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Receptors, Antigen, T-Cell, gamma-delta; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2935763
  •  go-up   go-down


64. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A: Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest; 2008 Mar;118(3):994-1005
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most importantly, when alphaGalCer/sCD1d was fused to a HER2-specific scFv antibody fragment, potent inhibition of experimental lung metastasis and established s.c. tumors was obtained when systemic treatment was started 2-7 days after the injection of HER2-expressing B16 melanoma cells.
  • [MeSH-minor] Animals. Antigens, CD1d. Cytotoxicity, Immunologic. Dendritic Cells / immunology. Female. Interferon-gamma / biosynthesis. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Sep 4;192(5):741-54 [10974039.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1720-7 [11385616.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1259-66 [11830474.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1670-8 [16849476.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7422-30 [17189415.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):727s-732s [17255301.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] Nat Immunol. 2002 Sep;3(9):867-74 [12154358.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3702-9 [12473579.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):267-79 [12874260.001]
  • [Cites] Cancer Immun. 2003 Aug 14;3:11 [12916958.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5140-7 [14607913.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):299-310 [14551186.001]
  • [Cites] Blood. 2004 Jan 15;103(2):383-9 [14512316.001]
  • [Cites] Int Immunol. 2004 Feb;16(2):241-7 [14734609.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1607-18 [15197224.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):909-14 [10837418.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):107-14 [6537909.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1285-95 [7908323.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4758-65 [8840995.001]
  • [Cites] Science. 1997 Feb 14;275(5302):977-9 [9020080.001]
  • [Cites] Annu Rev Immunol. 1997;15:535-62 [9143699.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):109-20 [9207002.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1626-9 [9374463.001]
  • [Cites] FEBS Lett. 1998 May 15;427(3):357-61 [9637257.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4647-50 [10528160.001]
  • [Cites] Science. 2004 Dec 3;306(5702):1786-9 [15539565.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1800-11 [15599405.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1910-7 [15756017.001]
  • [Cites] Annu Rev Immunol. 2005;23:877-900 [15771592.001]
  • [Cites] Nature. 2005 Mar 24;434(7032):525-9 [15791258.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1503-17 [15867097.001]
  • [Cites] Biotechnol Prog. 2005 Jan-Feb;21(1):148-53 [15903252.001]
  • [Cites] J Exp Med. 2005 Jun 20;201(12):1973-85 [15967825.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3092-101 [16116198.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2572-83 [16138194.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1279-88 [16275765.001]
  • [Cites] J Exp Med. 2005 Dec 19;202(12):1627-33 [16365146.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1207-10 [16369561.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S82-6 [16399439.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4305-11 [11035065.001]
  • (PMID = 18259610.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400421; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD1d; 0 / Antineoplastic Agents; 0 / Galactosylceramides; 0 / Immunoglobulin Fragments; 0 / Recombinant Fusion Proteins; 0 / alpha-galactosylceramide; 0 / immunoglobulin Fv; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2230658
  •  go-up   go-down


65. Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ: Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res; 2007 Jul 1;67(13):6468-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report that growth of the poorly immunogenic B16 melanoma in the absence of regulatory T cells (T(reg)) generates CD8 T-cell responses that develop into functional memory after the tumor has been surgically excised.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):582-92 [16224276.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Science. 2006 Apr 7;312(5770):114-6 [16513943.001]
  • [Cites] Immunol Rev. 2006 Jun;211:214-24 [16824130.001]
  • [Cites] J Virol. 2006 Sep;80(17):8303-15 [16912282.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):2214-20 [10657677.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1095-9 [11221838.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):953-66 [11581317.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1743-50 [11912149.001]
  • [Cites] Immunol Rev. 2002 Oct;188:122-35 [12445286.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1585-92 [12486101.001]
  • [Cites] Cell. 2002 Dec 13;111(6):837-51 [12526810.001]
  • [Cites] Nat Immunol. 2003 Mar;4(3):225-34 [12563257.001]
  • [Cites] Science. 2003 Apr 11;300(5617):337-9 [12690201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] J Exp Med. 2003 Aug 18;198(4):569-80 [12925674.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):889-901 [12975455.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):1023-34 [14530375.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5940-7 [14634105.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1491-500 [14734726.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2205-11 [15026364.001]
  • [Cites] Nat Immunol. 2004 Aug;5(8):809-17 [15247915.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):2923-7 [15322149.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):927-33 [15300249.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):689-96 [6643767.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1312-21 [6232336.001]
  • [Cites] Int J Cancer. 1986 Feb 15;37(2):275-81 [3943923.001]
  • [Cites] Arch Dermatol. 1987 Aug;123(8):1053-5 [3631983.001]
  • [Cites] J Immunol. 1994 Jan 15;152(2):405-12 [7904288.001]
  • [Cites] J Exp Med. 1997 Feb 3;185(3):453-9 [9053445.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):277-86 [9670040.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1641-50 [9802976.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] J Natl Cancer Inst. 1957 Jun;18(6):769-78 [13502695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9 [15505208.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):88-93 [15744305.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3419-27 [15833877.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):326-32 [15886125.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1591-602 [15883172.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):123-33 [15983064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):919-29 [16186184.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3301-5 [16517695.001]
  • (PMID = 17616708.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016437; United States / NCRR NIH HHS / RR / P20 RR016437-060010; United States / NCI NIH HHS / CA / R01 CA120777; United States / NCRR NIH HHS / RR / P20 RR16437; United States / NCI NIH HHS / CA / CA120777-02; United States / NCRR NIH HHS / RR / P20 RR016437-050010; United States / NCI NIH HHS / CA / CA120777-01; United States / NCRR NIH HHS / RR / RR016437-050010; United States / NCI NIH HHS / CA / CA103642; United States / NCI NIH HHS / CA / R01 CA120777-01; United States / NCI NIH HHS / CA / R01 CA103642; United States / NCI NIH HHS / CA / R01 CA120777-02; United States / NCRR NIH HHS / RR / RR016437-060010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS70542; NLM/ PMC2564800
  •  go-up   go-down


66. Qian F, Li YP, Sheng X, Zhang ZC, Song R, Dong W, Cao SX, Hua ZC, Xu Q: PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med; 2007 Mar-Apr;13(3-4):151-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
  • However, the effect of PRL-3 on spontaneous metastasis has not been clearly demonstrated, and whether PRL-3 could become a new therapeutic target in malignant tumor is still unknown.
  • In this study, we used PRL-3 siRNA as a molecular medicine to specifically reduce the expression of PRL-3 in B16-BL6 cells, a highly metastatic melanoma cell line.
  • Therefore, our results indicate that PRL-3 plays a critical role in promoting the whole process of spontaneous metastasis and tumor growth initiation, and that inhibiting PRL-3 will improve malignant tumor therapy.
  • [MeSH-major] Immediate-Early Proteins / metabolism. Melanoma, Experimental / pathology. Melanoma, Experimental / physiopathology. Neoplasm Metastasis / prevention & control. Protein Tyrosine Phosphatases / metabolism. RNA, Small Interfering / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):13957-63 [16543245.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Clin Exp Metastasis. 2000;18(5):415-21 [11467774.001]
  • [Cites] Mol Med. 2001 Mar;7(3):149-58 [11471551.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Mol Med. 2001 Dec;7(12):816-30 [11844870.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44187-94 [12218048.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1401-3 [14585643.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):167-77 [12883995.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Mol Med. 2004 Jan-Jun;10(1-6):6-11 [15502877.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Metastasis Rev. 1996 Mar;15(1):77-89 [8842480.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Mol Ther. 2005 Feb;11(2):267-74 [15668138.001]
  • [Cites] Cancer Gene Ther. 2005 May;12(5):456-63 [15719029.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1269-75 [15979576.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):803-12 [16112910.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1653-61 [16275986.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):800-6 [16467091.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1308-16 [16489088.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [ErratumIn] Mol Med. 2007 May-Jun;13(5-6):325
  • (PMID = 17592549.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / Ptp4a3 protein, mouse; 0 / RNA, Small Interfering; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC1892759
  •  go-up   go-down


67. Sato A, McNulty L, Cox K, Kim S, Scott A, Daniell K, Summerville K, Price C, Hudson S, Kiakos K, Hartley JA, Asao T, Lee M: A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem; 2005 Jun 2;48(11):3903-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Continuous exposure of human (K562) and murine (B16, L1210 and P815) cancer cell lines to the compounds demonstrated their significant cytotoxicity, with IC50 values in the sub-micromolar range.
  • According to NCI's cytotoxicity screen, compounds 11a and 12 were active against human cancer cell lines derived from lung, colon, melanoma, renal system, and breast.
  • At the respective doses of 15 and 20 mg/kg (administered via an ip route), compounds 11a and 12 inhibited the growth of murine B16-F0 melanoma in C57BL/6 mice, with minimal toxicity, and 11a gave a significant anticancer effect.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1-NAPHTHYLAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916443.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(2-chloroethyl)-3-(5,6,7-trimethoxyindolyl-2-carboxamido)-1-naphthylamine; 0 / Antineoplastic Agents; 0 / Cyclopropanes; 0 / Indole Alkaloids; 0 / Indoles; 0 / Naphthalenes; 69866-21-3 / CC 1065; 9007-49-2 / DNA; 9753I242R5 / 1-Naphthylamine
  •  go-up   go-down


68. Vasconcellos MC, Montenegro RC, Militão GC, Fonseca AM, Pessoa OD, Lemos TL, Pessoa C, Moraes MO, Costa-Lotufo LV: Bioactivity of biflorin, a typical o-naphthoquinone isolated from Capraria biflora L. Z Naturforsch C; 2005 May-Jun;60(5-6):394-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biflorin lacked activity on mouse erythrocytes as well as on the development of sea urchin eggs, but strongly inhibited the growth of all five tested tumor cell lines, especially the skin, breast and colon cancer cells with IC50 of 0.40, 0.43 and 0.88 micro/ml for B16, MCF-7 and HCT-8, respectively.
  • [MeSH-minor] Animals. Breast Neoplasms. Cell Line, Tumor. Colonic Neoplasms. Female. HL-60 Cells. Humans. Leukemia. Melanoma, Experimental. Mice. Mitosis / drug effects. Ovum / cytology. Ovum / drug effects. Plant Roots / chemistry. Sea Urchins

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. 1,2-NAPHTHOQUINONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042338.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Naphthoquinones; 804K62F61Q / 1,2-naphthoquinone
  •  go-up   go-down


69. Zheng ZB, Zhu G, Tak H, Joseph E, Eiseman JL, Creighton DJ: N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities. Bioconjug Chem; 2005 May-Jun;16(3):598-607
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, B16 melanotic melanoma in culture is inhibited by poly-HPMA-8-sulfoxide and by poly-HPMA-7 with IC(50) values of 168 +/- 8 and 284 +/- 5 microM, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898727.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA59612
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Alkylating Agents; 0 / Antineoplastic Agents; 0 / Polymers; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide; 9007-49-2 / DNA; EC 4.4.1.5 / Lactoylglutathione Lyase; GAN16C9B8O / Glutathione
  •  go-up   go-down


70. Curto-Reyes V, Juárez L, García-Pérez E, Fresno MF, Hidalgo A, Menéndez L, Baamonde A: Local loperamide inhibits thermal hyperalgesia but not mechanical allodynia induced by intratibial inoculation of melanoma cells in mice. Cell Mol Neurobiol; 2008 Nov;28(7):981-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local loperamide inhibits thermal hyperalgesia but not mechanical allodynia induced by intratibial inoculation of melanoma cells in mice.
  • In C57BL/6 mice intratibially inoculated with B16-F10 melanoma cells, the progressive tumoral damage was accompanied by the establishment of thermal hyperalgesia (unilateral hot plate test) and mechanical allodynia (von Frey test).
  • Overall, the present results show that the intratibial inoculation of B16-F10 cells to C57BL/6 mice evokes thermal hyperalgesia and mechanical allodynia and that, as occurred in the osteosarcoma model, the stimulation of peripheral opioid receptors is not effective in modifying neoplastic allodynia but completely inhibits thermal hyperalgesia through the activation of the NO/cGMP/K+ (ATP) cascade.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Aug;9(8):1003-8 [12894165.001]
  • [Cites] IDrugs. 2001 Jul;4(7):795-803 [15995936.001]
  • [Cites] Neurosci Lett. 2004 Apr 22;360(1-2):85-9 [15082185.001]
  • [Cites] Clin Exp Metastasis. 2005;22(5):403-11 [16283483.001]
  • [Cites] CNS Drug Rev. 2007 Fall;13(3):279-95 [17894645.001]
  • [Cites] Curr Med Chem. 2007;14(18):1945-55 [17691937.001]
  • [Cites] Peptides. 2006 Nov;27(11):2778-85 [16930772.001]
  • [Cites] Q J Nucl Med. 2001 Mar;45(1):53-64 [11456376.001]
  • [Cites] J Neurosci Methods. 1994 Jul;53(1):55-63 [7990513.001]
  • [Cites] Pain. 2003 Dec;106(3):347-56 [14659517.001]
  • [Cites] Pain. 2007 Jan;127(1-2):84-93 [16963185.001]
  • [Cites] Eur J Pharmacol. 2002 Apr 26;441(3):185-91 [12063091.001]
  • [Cites] Brain Res. 2003 Apr 18;969(1-2):102-9 [12676370.001]
  • [Cites] Neuropharmacology. 2007 Jul;53(1):71-80 [17543351.001]
  • [Cites] Pharmacol Biochem Behav. 2005 May;81(1):114-21 [15894068.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):550-8 [12594809.001]
  • [Cites] Pain. 2005 Nov;118(1-2):125-36 [16154703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3680-5 [14990791.001]
  • [Cites] J Pharmacol Sci. 2003 Feb;91(2):167-70 [12686763.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Sep;82(1):109-19 [16125759.001]
  • [Cites] Ann Neurol. 2003 Mar;53(3):366-75 [12601704.001]
  • [Cites] J Neurosci Methods. 2002 Jan 15;113(1):91-7 [11741726.001]
  • [Cites] Neurosci Lett. 2007 Jan 10;411(2):143-6 [17110034.001]
  • [Cites] Neuroscience. 2000;98(3):585-98 [10869852.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):213-9 [16283255.001]
  • [Cites] J Pharmacol Sci. 2007 Jul;104(3):218-24 [17598951.001]
  • [Cites] Brain Res. 1997 Aug 1;764(1-2):126-32 [9295201.001]
  • [Cites] Pain. 2002 Mar;96(1-2):129-40 [11932069.001]
  • [Cites] Br J Clin Pharmacol. 1980 Oct;10 Suppl 2:237S-245S [6254551.001]
  • [Cites] Mol Imaging. 2006 Apr-Jun;5(2):105-14 [16954024.001]
  • [Cites] Eur J Pharmacol. 2003 Nov 28;481(2-3):203-6 [14642787.001]
  • [Cites] Pain. 2008 Jul;137(1):81-95 [17900807.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6876-81 [3180096.001]
  • [Cites] Life Sci. 2007 Aug 2;81(8):673-82 [17692876.001]
  • [Cites] Exp Neurol. 2004 Apr;186(2):173-97 [15026255.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):900-10 [16952558.001]
  • [Cites] Pharmacol Biochem Behav. 2007 Mar;86(3):458-67 [17306872.001]
  • [Cites] Neuroreport. 2003 May 6;14(6):867-9 [12858049.001]
  • (PMID = 18360770.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Enzyme Inhibitors; 0 / KATP Channels; 0 / Potassium Channel Blockers; 0 / Receptors, Opioid; 31C4KY9ESH / Nitric Oxide; 6X9OC3H4II / Loperamide; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


71. Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H: Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res; 2006 Jul 1;12(13):4055-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells.
  • In this study, we explore the effects of ex vivo and in vivo delivery of short interfering RNA (siRNA) targeting tissue factor on B16 melanoma colonization of the lung in a murine model for metastasis.
  • EXPERIMENTAL DESIGN AND RESULTS: C57BL/6 mice were evaluated for pulmonary metastases following tail vein injection of B16 cells transfected with either active or inactive siRNA.
  • [MeSH-major] Drug Delivery Systems. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy. RNA, Small Interfering / administration & dosage. Thromboplastin / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818705.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 9035-58-9 / Thromboplastin
  •  go-up   go-down


72. Abduvaliev AA, Gil'dieva MS: [Differential trypan blue staining of tumor cells for the determination of apoptosis]. Klin Lab Diagn; 2006 Feb;(2):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paper also gives data of the comparative studies of the content of apoptotic cells in experimental melanoma B-16 though differential trypan blue staining and classical morphostructural analysis.
  • [MeSH-major] Apoptosis. Breast Neoplasms / pathology. Coloring Agents. Immunohistochemistry. Melanoma / pathology. Trypan Blue

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. Trypan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610632.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Coloring Agents; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


73. Akihisa T, Seino K, Kaneko E, Watanabe K, Tochizawa S, Fukatsu M, Banno N, Metori K, Kimura Y: Melanogenesis inhibitory activities of iridoid-, hemiterpene-, and fatty acid-glycosides from the fruits of Morinda citrifolia (Noni). J Oleo Sci; 2010;59(1):49-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new iridoid glycoside, 9-epi-6alpha-methoxy geniposidic acid (4), three new hemiterpene glycosides, 3-methylbut-3-enyl 2'-O-(beta-D-glucopyranosyl)-beta-D-glucopyranoside (nonioside K) (6), 3-methylbut-3-enyl 6'-O-(beta-D-xylopyranosyl)-beta-D-glucopyranoside (nonioside L) (8), and 3-methylbut-3-enyl 6'-O-(beta-D-xylofuranosyl)-beta-D-glucopyranoside (nonioside M) (9), and two new saccharide fatty acid esters, 6'-O-(beta-D-glucopyranosyl)-1'-O-[(2xi)-2-methylbutanoyl]-beta-D-glucopyranose (nonioside N) (16) and 6'-O-(beta-D-xylopyranosyl)-1'-O-[(2xi)-2-methylbutanoyl]-beta-D-glucopyranose (nonioside O) (17), were isolated from a methanol extract of the fruits of Morinda citrifolia (noni), along with 11 known compounds, namely, three iridoid glycosides (1-3), two hemiterpene glycosides (5 and 7), and five saccharide fatty acid esters (10-15).
  • Upon evaluation of compounds 1-17 on the melanogenesis in the B16 melanoma cells induced with alpha-melanocyte-stimulating hormone (alpha-MSH), 13 compounds (1, 3, 4, 6-14, and 17) exhibited marked inhibitory effects with 34-49% reduction of melanin content at 100 muM with no or almost no toxicity to the cells (91-116% of cell viability at 100 microM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032599.001).
  • [ISSN] 1347-3352
  • [Journal-full-title] Journal of oleo science
  • [ISO-abbreviation] J Oleo Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids; 0 / Glycosides; 0 / Iridoids; 0 / Melanins; 0 / Plant Preparations; 0 / Terpenes
  •  go-up   go-down


74. Amsen EM, Pham N, Pak Y, Rotin D: The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells. J Biol Chem; 2006 Jan 6;281(1):121-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells.
  • cAMP-dependent Ras activation has been demonstrated in numerous cell types, particularly of neuronal (including melanoma cells) and endocrine origin, but the Ras activator involved has not been identified.
  • In B16 melanoma cells, cAMP activates the Ras/Erk pathway, leading initially to stimulation but subsequently to long term (>24-h) inhibition of melanogenesis (dendrite extension and melanin production).
  • We demonstrate that CNrasGEF is expressed endogenously in B16 melanoma cells and that cAMP-mediated activation of Ras and Erk1/2 in these cells can be augmented by CNrasGEF overexpression and reduced by its knockdown by RNA interference.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / genetics. Guanine Nucleotide Exchange Factors / metabolism. Melanins / metabolism. Melanoma / metabolism


75. Navarini AL, Chiaradia LD, Mascarello A, Fritzen M, Nunes RJ, Yunes RA, Creczynski-Pasa TB: Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion. Eur J Med Chem; 2009 Apr;44(4):1630-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion.
  • Searching for leading compounds of new drugs for cancer therapy, we studied the toxicity of 13 hydroxychalcones never tested before toward melanoma cell line (B16-F10).
  • Two of them induced mitochondrial GSH and ATP depletion and promoted cell death through apoptosis in melanoma cells.
  • One of the compounds induced cell death through necrosis but did not significantly decrease the intracellular mitochondrial GSH and ATP levels in melanoma cells.
  • [MeSH-major] Adenosine Triphosphate / metabolism. Apoptosis / drug effects. Chalcone / chemistry. Chalcone / pharmacology. Glutathione / metabolism. Melanoma / metabolism. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211173.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5S5A2Q39HX / Chalcone; 8L70Q75FXE / Adenosine Triphosphate; GAN16C9B8O / Glutathione
  •  go-up   go-down


76. Delli Castelli D, Dastrù W, Terreno E, Cittadino E, Mainini F, Torres E, Spadaro M, Aime S: In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. J Control Release; 2010 Jun 15;144(3):271-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paramagnetically loaded liposomes were injected directly into the tumor (B16 melanoma xenograft in mice) where they generate T(1), T(2), and CEST MR contrasts that were quantitatively monitored over time (0-48h).
  • [MeSH-major] Contrast Media / pharmacokinetics. Liposomes / pharmacokinetics. Magnetic Resonance Imaging. Magnetics. Melanoma, Experimental / metabolism

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230865.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Liposomes; 0 / Organometallic Compounds; 0 / thulium(III) 1,4,7,10-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate; 0199MV609F / gadoteridol; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


77. Lentini A, Tabolacci C, Mattioli P, Provenzano B, Beninati S: Antitumor activity of theophylline in combination with Paclitaxel: a preclinical study on melanoma experimental lung metastasis. Cancer Biother Radiopharm; 2010 Aug;25(4):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of theophylline in combination with Paclitaxel: a preclinical study on melanoma experimental lung metastasis.
  • Melanoma is one of the most aggressive forms of tumor, being responsible for about 80% of skin cancer deaths.
  • The present study was undertaken to examine the possible role of a combination therapy using paclitaxel (PTX) as chemotherapeutic molecule and theophylline (TH) as differentiative agent in the prevention of metastasis in B16-F10 melanoma-bearing C57BL6/N mice.
  • In the in vivo experiments, a highly sensitive computerized image analysis method, performed on histological lung sections of mice injected with melanoma cells, was used to quantify the efficacy of the treatments.
  • [MeSH-major] Cell Proliferation / drug effects. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Paclitaxel / therapeutic use. Theophylline / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735210.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Vasodilator Agents; C137DTR5RG / Theophylline; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


78. Takahashi S, Iwai H, Kosaka K, Miyazaki T, Osanai Y, Arao N, Tanaka K, Nagai K, Nakagawa A: Byelyankacin: a novel melanogenesis inhibitor produced by Enterobacter sp. B20. J Antibiot (Tokyo); 2007 Nov;60(11):717-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1 potently inhibited mushroom tyrosinase and melanogenesis of B16-2D2 melanoma cells with IC50 value of 2.1 nM and 30 nM, respectively.
  • [MeSH-minor] Cell Line, Tumor. Culture Media / chemistry. Fermentation. Humans. Magnetic Resonance Spectroscopy. Melanoma, Experimental / metabolism. Monophenol Monooxygenase / antagonists & inhibitors. Spectrophotometry, Infrared. Spectrophotometry, Ultraviolet

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057703.001).
  • [ISSN] 0021-8820
  • [Journal-full-title] The Journal of antibiotics
  • [ISO-abbreviation] J. Antibiot.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 4-(2-isocyanovinyl)phenyl alpha-L-rhamnopyranoside; 0 / Culture Media; 0 / Melanins; 0 / Monosaccharides; 0 / Nitriles; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


79. Berridge MV, Tan AS: Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res; 2010 Apr-Jun;13(2-3):139-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect.
  • We have employed an extreme model of glycolytic metabolism to investigate the ability of metastatic B16 mouse melanoma cells to grow as primary subcutaneous tumors and to form lung tumors when injected intravenously into syngeneic and immunocompromised mice.
  • [MeSH-major] Gene Deletion. Genes, Mitochondrial. Melanoma, Experimental / genetics. Melanoma, Experimental / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370492.001).
  • [ISSN] 1557-8577
  • [Journal-full-title] Rejuvenation research
  • [ISO-abbreviation] Rejuvenation Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species
  •  go-up   go-down


80. Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, Nowsheen S, Kryston TB, Bonner WM, Georgakilas AG, Sedelnikova OA: Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci U S A; 2010 Oct 19;107(42):17992-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this question, we examined tissues distant to sites of implanted tumors for genomic damage using cohorts of C57BL/6 and BALB/c mice with early-stage subcutaneous syngeneic grafts, specifically, B16 melanoma, MO5076 sarcoma, and COLON26 carcinoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2010 Jan 14;29(2):273-84 [19802007.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] Am J Respir Cell Mol Biol. 2011 Feb;44(2):230-7 [20395632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7426-30 [11404468.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Aug;285(2):C353-69 [12686516.001]
  • [Cites] Mutat Res. 2003 Oct 29;531(1-2):93-107 [14637248.001]
  • [Cites] Mutagenesis. 2004 May;19(3):169-85 [15123782.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1663-72 [15185308.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):149-54 [15246049.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):152-8 [9618134.001]
  • [Cites] Circ Res. 2005 Apr 29;96(8):881-9 [15774854.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7257-65 [16170376.001]
  • [Cites] Cell Immunol. 2005 Jun;235(2):122-35 [16243300.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):113-8 [16413041.001]
  • [Cites] Blood. 2007 Feb 1;109(3):987-94 [17032917.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):993-1002 [16909103.001]
  • [Cites] Radiat Res. 2007 Feb;167(2):207-16 [17390728.001]
  • [Cites] Thromb Haemost. 2007 May;97(5):714-21 [17479181.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4295-302 [17483342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1543-6 [17684126.001]
  • [Cites] Mol Biosyst. 2008 Jan;4(1):30-5 [18075671.001]
  • [Cites] Aging Cell. 2008 Jan;7(1):89-100 [18005250.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1507-10 [18483401.001]
  • [Cites] Hum Mol Genet. 2008 Apr 15;17(R1):R54-9 [18632698.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):428-35 [18650913.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12445-50 [18711141.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7059-65 [18757420.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):957-67 [19005492.001]
  • [Cites] Mucosal Immunol. 2008 Jan;1(1):31-7 [19079158.001]
  • [Cites] PLoS Biol. 2008 Dec 2;6(12):2853-68 [19053174.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Mutat Res. 2009 Mar 31;674(1-2):131-6 [18948225.001]
  • [Cites] Nat Rev Cancer. 2009 May;9(5):351-60 [19377507.001]
  • [Cites] J Interferon Cytokine Res. 2009 Jun;29(6):313-26 [19441883.001]
  • [Cites] Curr Pharm Des. 2009;15(17):1949-55 [19519435.001]
  • [Cites] Annu Rev Physiol. 2009;71:241-60 [18808327.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7884-92 [19773434.001]
  • [Cites] Carcinogenesis. 2009 Oct;30(10):1686-95 [19651821.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17861-2 [20926747.001]
  • (PMID = 20855610.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2964229
  •  go-up   go-down


81. Toomey D, Conroy H, Jarnicki AG, Higgins SC, Sutton C, Mills KH: Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine; 2008 Jun 25;26(27-28):3540-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma.
  • Therapeutic administration of DC pulsed in vitro with Hsp70 in the presence of a COX-2 inhibitor significantly reduced progression of B16 tumors in mice and significantly enhanced survival.
  • [MeSH-major] Cyclooxygenase 2 Inhibitors / pharmacology. Dendritic Cells / immunology. HSP70 Heat-Shock Proteins / immunology. Immunotherapy, Adoptive / methods. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479787.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, CD80; 0 / Cyclooxygenase 2 Inhibitors; 0 / HSP70 Heat-Shock Proteins; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


82. Yang J, Guo H, Gallazzi F, Berwick M, Padilla RS, Miao Y: Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem; 2009 Aug 19;20(8):1634-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.
  • The purpose of this study was to determine whether Arg-Gly-Asp (RGD)-conjugated α-melanocyte stimulating hormone (α-MSH) hybrid peptide could be employed to target melanocortin-1 (MC1) receptor for potential melanoma therapy.
  • The MC1 receptor binding affinity of RGD-Lys-(Arg(11))CCMSH was determined in B16/F1 melanoma cells.
  • The internalization and efflux, melanoma targeting and pharmacokinetic properties and single photon emission computed tomography/CT (SPECT/CT) imaging of (99m)Tc-RGD-Lys-(Arg(11))CCMSH were determined in B16/F1 melanoma cells and melanoma-bearing C57 mice.
  • Clonogenic cytotoxic effect of RGD-Lys-(Arg(11))CCMSH was examined in B16/F1 melanoma cells.
  • RESULTS: RGD-Lys-(Arg(11))CCMSH displayed 2.1 nM MC1 receptor binding affinity. (99m)Tc-RGD-Lys-(Arg(11))CCMSH showed rapid internalization and extended retention in B16/F1 cells.
  • The cellular uptake of (99m)Tc-RGD-Lys-(Arg(11))CCMSH was MC1 receptor-mediated. (99m)Tc-RGD-Lys-(Arg(11))CCMSH exhibited high tumor uptake (14.83 ± 2.94% ID/g 2 h postinjection) and prolonged tumor retention (7.59 ± 2.04% ID/g 24 h postinjection) in B16/F1 melanoma-bearing mice.
  • Flank melanoma tumors were clearly imaged by small animal SPECT/CT using (99m)Tc-RGD-Lys-(Arg(11))CCMSH as an imaging probe 2 h postinjection.
  • Single treatment (3 h incubation) with 100 nM of RGD-Lys-(Arg(11))CCMSH significantly (p < 0.05) decreased the clonogenic survival of B16/F1 cells by 65% compared to the untreated control cells.
  • CONCLUSION: Favorable melanoma targeting property of (99m)Tc-RGD-Lys-(Arg(11))CCMSH and remarkable cytotoxic effect of RGD-Lys-(Arg(11))CCMSH in B16/F1 cells warranted the further evaluation of (188)Re-labeled α-MSH hybrid peptides as novel therapeutic peptides for melanoma treatment once the strategies of amino acid coinjection or structural modification of peptide sequence substantially reduce the renal uptake.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / therapeutic use. Melanoma, Experimental / drug therapy. Oligopeptides / chemistry. alpha-MSH / chemistry. alpha-MSH / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Nature. 1999 Feb 11;397(6719):534-9 [10028971.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:191S-8S [15653669.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]
  • [Cites] Curr Opin Chem Biol. 2005 Aug;9(4):352-8 [16023401.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):122-9 [16391196.001]
  • [Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]
  • [Cites] Curr Med Chem. 2000 Sep;7(9):971-94 [10911025.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):716-23 [10925366.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):707-14 [7804999.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4263-72 [12154028.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):480-7 [12216078.001]
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):469-75 [12432548.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):173-80 [15186597.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1716-20 [15471839.001]
  • [Cites] Endocrinology. 1987 Nov;121(5):1900-7 [2822378.001]
  • [Cites] Cancer Res. 1989 Nov 15;49(22):6352-8 [2804981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • (PMID = 19552406.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA118100; United States / NCI NIH HHS / CA / P30 CA118100
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligopeptides; 581-05-5 / alpha-MSH; 7440-26-8 / Technetium; 99896-85-2 / arginyl-glycyl-aspartic acid
  • [Other-IDs] NLM/ NIHMS450313; NLM/ PMC3621710
  •  go-up   go-down


83. Olszewska-Słonina DM, Styczyński J, Czajkowski R, Drewa TA, Musiałkiewicz D: Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs. Acta Pol Pharm; 2007 Sep-Oct;64(5):469-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs.
  • In this work the influence of some cytostatic drugs (at EC50) on melanin content and on the apoptotic processes in mouse melanoma B16 and Cloudman S91 cells in vitro were investigated.
  • The number of viable mouse melanoma B16 and Cloudman S91 cells was estimated by flow cytometry analysis and melanin content in colorimetric assays.
  • The majority of tested cytostatic drugs caused an increase of melanin content in the cells of both melanoma lines, except cisplatin and dacarbazine in the case of B16 cells and dacarbazine in the case of Cloudman S91.
  • Slight increase of melanin content in melanoma cells can be a cell answer to free radicals generation by some cytostatic drugs like adriblastin, actinomycin D and vincristine.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Melanins / analysis. Melanoma, Experimental / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540169.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Melanins; 04079A1RDZ / Cytarabine; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Mesojednik S, Rols MP, Teissie J: Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther; 2009 May;16(5):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of reporter genes was higher in B16 melanoma than in SA-1 fibrosarcoma.
  • [MeSH-major] DNA / administration & dosage. Electroporation / methods. Fibrosarcoma / metabolism. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212425.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


85. Li H, Xiang ZM, Wu XL, Wang L, Wei HF, Wan M, Wang LY, Yu YL: [Establishment of a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jan;25(1):13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo].
  • AIM: To establish a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo.
  • METHODS: Eukaryotic expressing vector pcDNA3-GFP-HER2 was constructed by molecular cloning technique and transfected into B16 cells mediated by cationic liposome.
  • The GFP-HER2 positive cells were isolated from tumor burdening mice by flow cytometry (FCM) sorting, and then monoclonized in the absence of G418 to obtain a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo.
  • RESULTS: Restriction endonulease analysis and DNA sequencing showed that the pcDNA3-GFP-HER2 was constructed and a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo was obtained successfully.
  • CONCLUSION: A B16 cell line stably expressing genes encoding HER2 multi-epitope peptides is established successfully, which would provide a method to establish other cell lines stably expressing exogenous genes.
  • [MeSH-major] Epitopes / immunology. Melanoma, Experimental / pathology. Peptide Fragments / immunology. Peptide Fragments / metabolism. Receptor, ErbB-2 / immunology. Receptor, ErbB-2 / metabolism. Recombinant Fusion Proteins / immunology. Recombinant Fusion Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126380.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Epitopes; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


86. Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J: CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol; 2009 Jan 1;182(1):193-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4(+) Th-APC with acquired pMHC II and I were capable of stimulating CD4(+) Th1 and central memory CD8(+)44(+)CD62L(high)IL-7R(+) T cell responses leading to antitumor immunity against OVA-expressing mouse B16 melanoma.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, CD44 / biosynthesis. Cell Line, Tumor. Cytotoxicity Tests, Immunologic. L-Selectin / biosynthesis. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Molecular Sequence Data. Receptors, Interleukin-7 / biosynthesis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109150.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / Peptide Fragments; 0 / Receptors, Interleukin-7; 126880-86-2 / L-Selectin
  •  go-up   go-down


87. Saji H, Song W, Furumoto K, Kato H, Engleman EG: Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res; 2006 Apr 15;12(8):2568-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: BALB/c or C57Bl/6 mice were injected s.c. with CT26 colorectal carcinoma cells and B16 melanoma cells, respectively, and following 10 to 12 days of tumor growth, the tumors were treated with PDT alone or PDT followed by IT-DC or IT-PBS.
  • RESULTS: Whereas neither PDT nor IT-DC alone was effective, PDT + IT-DC eradicated both CT26 and B16 tumors in a significant proportion of animals and prolonged the survival of mice of which the tumors were not cured.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Apr 15;12(8):2385-9 [16638842.001]
  • (PMID = 16638867.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL57443; United States / NCI NIH HHS / CA / K08CA105064
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT: Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A; 2009 Jan 27;106(4):1193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.
  • This study demonstrates that in malignant melanoma, elevated levels of nuclear beta-catenin in both primary tumors and metastases correlate with reduced expression of a marker of proliferation and with improved survival, in contrast to colorectal cancer.
  • The reduction in proliferation observed in vivo is recapitulated in B16 murine melanoma cells and in human melanoma cell lines cultured in vitro with either WNT3A or small-molecule activators of beta-catenin signaling.
  • Consistent with these results, B16 melanoma cells expressing WNT3A also exhibit decreased tumor size and decreased metastasis when implanted into mice.
  • Genome-wide transcriptional profiling reveals that WNT3A up-regulates genes implicated in melanocyte differentiation, several of which are down-regulated with melanoma progression.
  • These findings suggest that WNT3A can mediate transcriptional changes in melanoma cells in a manner reminiscent of the known role of Wnt/beta-catenin signaling in normal melanocyte development, thereby altering melanoma cell fate to one that may be less proliferative and potentially less aggressive.
  • Our results may explain the observed loss of nuclear beta-catenin with melanoma progression in human tumors, which could reflect a dysregulation of cellular differentiation through a loss of homeostatic Wnt/beta-catenin signaling.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1923-6 [10489374.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):753-5 [12952929.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3383-8 [12960126.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):367-77 [12967557.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1401-8 [14977843.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2264-74 [14755246.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5215-26 [15133491.001]
  • [Cites] Pigment Cell Res. 2004 Aug;17(4):318-25 [15250933.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):245-51 [15254684.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1251-8 [15205682.001]
  • [Cites] Nat Rev Genet. 2004 Sep;5(9):691-701 [15372092.001]
  • [Cites] Cell. 1987 Aug 14;50(4):649-57 [3111720.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):158-62 [10652270.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):140-51 [11223543.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):568-76 [11208852.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):839-42 [11351304.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):210-6 [11531781.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1172-83 [11809808.001]
  • [Cites] Melanoma Res. 2002 Apr;12(2):183-6 [11930117.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):549-56 [12124804.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):361-9 [12170439.001]
  • [Cites] J Cell Biol. 2002 Sep 16;158(6):1079-87 [12235125.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2479-86 [12467060.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1515-20 [9537257.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9277-80 [10430933.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3880-2 [10463574.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):237-50 [15986134.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14 [16361544.001]
  • [Cites] Stem Cells. 2006 Jul;24(7):1668-77 [16574754.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7833-6 [16912153.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):599-607 [16965333.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:267-86 [16803431.001]
  • [Cites] Front Biosci. 2007;12:448-57 [17127309.001]
  • [Cites] Science. 2007 Feb 2;315(5812):642-5 [17204608.001]
  • [Cites] Histopathology. 2007 Mar;50(4):453-64 [17448021.001]
  • [Cites] Science. 2007 May 18;316(5827):1043-6 [17510365.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17259-71 [17426020.001]
  • [Cites] PLoS One. 2007;2(7):e594 [17611626.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2923-35 [18006687.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):949-58 [18398036.001]
  • [Cites] Science. 2008 Apr 18;320(5874):365-9 [18420933.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2890-4 [18539969.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5825-32 [18794093.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):312-7 [12753406.001]
  • (PMID = 19144919.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / / ; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2626610
  •  go-up   go-down


89. Bellei B, Flori E, Izzo E, Maresca V, Picardo M: GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal; 2008 Oct;20(10):1750-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes.
  • Exposure of the murine melanoma cell line B16 and normal human melanocytes to GSK3beta specific inhibitors (SB216763, SB415286, BIO, and LiCl) resulted in a dose-dependent accumulation of beta-catenin.
  • Moreover, treatment of B16 cells with a siRNA targeted against beta-catenin completely abolished the promelanogenic effect of GSK3beta inhibition, however, the overexpression of a constitutively active mutant form of beta-catenin (pCS2beta-cat-mut) only slightly increased the degree of pigmentation.
  • [MeSH-major] Glycogen Synthase Kinase 3 / antagonists & inhibitors. Melanins / biosynthesis. Melanocytes / enzymology. Melanoma, Experimental / enzymology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602000.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / beta Catenin; EC 1.14.18.1 / Monophenol Monooxygenase; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  •  go-up   go-down


90. Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA: Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol; 2005 Jan 15;174(2):800-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells.
  • To investigate the in vivo role of 2B4, wild-type and 2B4(-/-) mice were injected with CD48(+) and CD48(-) metastatic B16 melanoma cells.
  • Wild-type mice rejected CD48(+) melanoma poorly compared with CD48(-) tumor cells, suggesting that ligation of 2B4 by CD48 on melanoma cells is inhibitory.
  • In keeping with this, male 2B4(-/-) mice showed enhanced ability to reject CD48(+) melanoma cells.
  • However, female 2B4(-/-) mice poorly rejected both CD48(+) and CD48(-) melanoma cells, revealing a gender-specific and CD48-independent defect in mice lacking 2B4.
  • [MeSH-major] Antigens, CD / genetics. Graft Rejection / genetics. Graft Rejection / immunology. Killer Cells, Natural / immunology. Melanoma, Experimental / genetics. Melanoma, Experimental / immunology. Membrane Glycoproteins / deficiency. Membrane Glycoproteins / genetics. Receptors, Immunologic / deficiency. Receptors, Immunologic / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634901.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85753
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD48 antigen; 0 / Cd244 protein, mouse; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic
  •  go-up   go-down


91. Liao YP, Wang CC, Schaue D, Iwamoto KS, McBride WH: Local irradiation of murine melanoma affects the development of tumour-specific immunity. Immunology; 2009 Sep;128(1 Suppl):e797-804
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local irradiation of murine melanoma affects the development of tumour-specific immunity.
  • Here we show that local radiation therapy of B16 melanoma tumours inhibits the development of systemic immunity to the melanoma antigen MART-1.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunology. 1999 Oct;98(2):181-8 [10540216.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4883-90 [18676762.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13257-62 [11069296.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):825-33 [11745485.001]
  • [Cites] Nat Immunol. 2002 Mar;3(3):237-43 [11875462.001]
  • [Cites] Science. 2002 Apr 12;296(5566):301-5 [11951032.001]
  • [Cites] Immunology. 2002 Jul;106(3):354-62 [12100723.001]
  • [Cites] Curr Pharm Des. 2002;8(19):1765-80 [12171547.001]
  • [Cites] J Exp Med. 2002 Oct 21;196(8):1091-7 [12391020.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1627-38 [12486105.001]
  • [Cites] Annu Rev Immunol. 2003;21:685-711 [12615891.001]
  • [Cites] BMC Immunol. 2001;2:8 [11532194.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8466-75 [14679011.001]
  • [Cites] Cell Biol Int. 2004;28(3):223-8 [14984749.001]
  • [Cites] Cancer Immunol Immunother. 2004 Mar;53(3):240-8 [14685779.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):685-90 [14999775.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):579-83 [15145179.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4328-37 [15205348.001]
  • [Cites] Radiat Res. 2004 Jul;162(1):1-19 [15222781.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2462-9 [15294960.001]
  • [Cites] Adv Immunol. 1976;24:215-335 [14486.001]
  • [Cites] Transplant Proc. 1979 Mar;11(1):1073-6 [313092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Dec;76(12):6591-5 [160568.001]
  • [Cites] Annu Rev Immunol. 1984;2:219-37 [6152690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):10104-7 [2602359.001]
  • [Cites] Science. 1993 Feb 12;259(5097):974-7 [8094901.001]
  • [Cites] J Immunol. 1993 Mar 15;150(6):2121-8 [8450205.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):8466-72 [8473290.001]
  • [Cites] Transplantation. 1994 Feb 27;57(4):582-92 [8116046.001]
  • [Cites] Exp Hematol. 1994 Jun;22(6):510-6 [8187847.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1074-7 [8189262.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):619-26 [7558951.001]
  • [Cites] Clin Exp Immunol. 1997 Feb;107(2):417-24 [9030884.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):71-81 [9206999.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2865-9 [9230191.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3899-903 [9307268.001]
  • [Cites] J Interferon Cytokine Res. 1997 Sep;17(9):567-72 [9335435.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):277-82 [9690456.001]
  • [Cites] J Immunother. 2005 Mar-Apr;28(2):129-35 [15725956.001]
  • [Cites] J Gene Med. 2005 Apr;7(4):506-17 [15580588.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7516-23 [15944250.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1082-92 [16841082.001]
  • [Cites] J Immunother. 2000 Jan;23(1):59-66 [10687138.001]
  • (PMID = 19740341.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087887; United States / NCI NIH HHS / CA / R01 CA101752; United States / NCI NIH HHS / CA / R01 CA101752:01; United States / NCI NIH HHS / CA / R01 CA87887:01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Mlana protein, mouse; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2753951
  •  go-up   go-down


92. Bezuhly M, Cullen R, Esmon CT, Morris SF, West KA, Johnston B, Liwski RS: Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood; 2009 Apr 2;113(14):3371-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro, B16-F10 melanoma cells showed decreased adhesion to and transmigration through endothelium treated with recombinant human aPC (rhaPC).
  • In murine B16-F10 metastasis models, transgenic EPCR overexpressing (Tie2-EPCR) mice exhibited marked reductions in liver (50%) and lung (92%) metastases compared with wild-type (WT) animals.
  • Intravital imaging showed reduced B16-F10 entrapment within livers of Tie2-EPCR compared with WT mice.
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Adhesion / genetics. Cell Movement / drug effects. Cell Movement / genetics. Female. Melanoma, Experimental / genetics. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Receptor, TIE-2 / genetics. Recombinant Proteins / pharmacology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188668.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 0 / Protein C; 0 / Receptors, Cell Surface; 0 / Recombinant Proteins; 0 / activated protein C receptor; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


93. Hata K, Hori K, Murata J, Takahashi S: Remodeling of actin cytoskeleton in lupeol-induced B16 2F2 cell differentiation. J Biochem; 2005 Oct;138(4):467-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remodeling of actin cytoskeleton in lupeol-induced B16 2F2 cell differentiation.
  • Lupeol induces the formation of dendrites in B16 2F2 melanoma cells.
  • The remodeling of cytoskeletal components contributes to the dendricity of melanoma cells.
  • We studied the effects of lupeol on the remodeling of cytoplasmic filaments in B16 2F2 cells.
  • We examined the activation of cofilin, an actin-depolymerizing factor, in lupeol-treated B16 2F2 cells by western blotting.
  • At 10 microM, lupeol markedly inhibited the haptotaxis of B16 2F2 cells to fibronectin.
  • Additionally, lupeol strongly inhibited the migration of human melanoma and neuroblastoma cells, and weakly suppressed the migration of lung adenocarcinoma cells.
  • The results suggest that lupeol suppresses the migration of malignant melanoma cells by disassembling the actin cytoskeleton.
  • [MeSH-major] Actin Cytoskeleton / drug effects. Actin Depolymerizing Factors / metabolism. Cell Differentiation / drug effects. Melanoma, Experimental / pathology. Triterpenes / pharmacology

  • Hazardous Substances Data Bank. LUPEOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272141.001).
  • [ISSN] 0021-924X
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actin Depolymerizing Factors; 0 / Pentacyclic Triterpenes; 0 / Triterpenes; O268W13H3O / lupeol
  •  go-up   go-down


94. Ortiz R, Prados J, Melguizo C, Rama AR, Segura A, Rodríguez-Serrano F, Boulaiz H, Hita F, Martinez-Amat A, Madeddu R, Ramos JL, Aranega A: The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo. J Mol Med (Berl); 2009 Sep;87(9):899-911
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.
  • Novel treatment modalities, including gene therapy, are needed for patients with advanced melanoma.
  • To evaluate whether this E gene has a cytotoxic impact on melanoma cells in vitro and in vivo, and could therefore be used as a new therapeutic strategy for this tumor type, we selected the B16-F10 murine melanoma cell line as a model.
  • We used a nonviral gene delivery approach (pcDNA3.1/E plasmid) to study the inhibition of melanoma cells' proliferation in vitro and direct intratumoral injection of pcDNA3.1/E complexed with jetPEI to deliver E cDNA to rapidly growing murine melanomas, and found that the E gene has both a strong antiproliferative effect in B16-F10 cells in vitro and induces an efficient decrease in melanoma tumor volume in vivo (90% in 15 days).
  • Interestingly, the GFP-E fusion protein expressed in melanoma cells was located in the mitochondria.
  • These results show that E gene expression in melanoma cells has an extraordinary antitumor effect, which means it may be a new candidate for an effective strategy for melanoma treatment.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. DNA, Viral / administration & dosage. Melanoma, Experimental. Mice. Mitochondria / drug effects. Mitochondrial Proteins / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2008 Aug;159(2):370-8 [18565182.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60 [18402522.001]
  • [Cites] FASEB J. 2008 Dec;22(12):4272-80 [18716030.001]
  • [Cites] Exp Dermatol. 2008 Jan;17(1):1-11 [18095940.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):191-201 [18502571.001]
  • [Cites] J Gene Med. 2008 Feb;10(2):113-22 [18076132.001]
  • [Cites] J Gene Med. 2006 Feb;8(2):229-41 [16170834.001]
  • [Cites] Int J Oncol. 2008 Jun;32(6):1245-51 [18497986.001]
  • [Cites] Cancer Gene Ther. 2007 Feb;14(2):165-73 [17008932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4297-302 [10760296.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1610-9 [16818521.001]
  • [Cites] Rev Recent Clin Trials. 2006 Sep;1(3):217-35 [18473975.001]
  • [Cites] Curr Opin Mol Ther. 2004 Aug;6(4):421-35 [15468601.001]
  • [Cites] J Virol. 1982 Dec;44(3):993-1002 [6294347.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):1005-12 [18507048.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1551-60 [15742333.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):117-27 [15015777.001]
  • [Cites] Bioorg Med Chem. 2008 May 1;16(9):5295-302 [18359635.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):121-7 [18575757.001]
  • [Cites] FEBS J. 2007 Sep;274(18):4825-36 [17714513.001]
  • [Cites] Eur J Biochem. 2003 Apr;270(8):1599-618 [12694174.001]
  • [Cites] FEMS Microbiol Lett. 1998 Jul 1;164(1):149-57 [9675861.001]
  • [Cites] Microbiology. 2006 Oct;152(Pt 10):2959-67 [17005977.001]
  • [Cites] Mol Ther. 2006 Nov;14(5):647-55 [16950655.001]
  • [Cites] Gene Ther. 2007 Jul;14(13):998-1009 [17443216.001]
  • [Cites] Cell Res. 2007 Dec;17(12):976-84 [18071367.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1584-90 [19039293.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):326-34 [10690507.001]
  • [Cites] J Gene Med. 2003 Mar;5(3):219-31 [12666188.001]
  • [Cites] J Invest Dermatol. 2005 Jan;124(1):221-8 [15654977.001]
  • [Cites] Mol Biotechnol. 2008 May;39(1):39-48 [18092145.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):445-9 [17245336.001]
  • [Cites] Cancer Gene Ther. 2006 Sep;13(9):845-55 [16710344.001]
  • [Cites] Arch Dermatol Res. 2001 Nov;293(10):484-90 [11820724.001]
  • (PMID = 19579018.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / Mitochondrial Proteins; 0 / Repressor Proteins; 0 / Viral Regulatory and Accessory Proteins; 0 / phage repressor proteins
  •  go-up   go-down


95. Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP: TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res; 2008 Apr;28(4):253-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model.
  • [MeSH-minor] Aminoquinolines / pharmacology. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Culture Media, Conditioned / pharmacology. Humans. Leukocytes, Mononuclear / drug effects. Lung / drug effects. Lung / pathology. Melanoma / pathology. Mice. Oligodeoxyribonucleotides / pharmacology. Subcellular Fractions / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439103.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / CpG ODN 2216; 0 / Culture Media, Conditioned; 0 / Interferon Type I; 0 / N-(4-(4-amino-2-ethyl-1H-imidazo(4,5c)quinolin-1-yl)butyl)methanesulfonamide; 0 / Oligodeoxyribonucleotides; 0 / Quinolines; 0 / Sulfonamides; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


96. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A: Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost; 2006 Dec;96(6):816-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the B16 melanoma mouse model of metastasis, subcutaneous (s.c.) injection of NA-LMWH or enoxaparin (10 mg/kg), three hours before intravenous (i.v.) injection of metastatic melanoma cells, followed by daily doses for 14 days, reduced lung tumor formation by 70% (P < 0.001). I.v. injection of tumor cells resulted in a significant (50-62%, P < 0.01) fall in platelet counts.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thromb Hemost. 1992;18(4):353-72 [1470924.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3632-7 [8101764.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):53-66 [7516417.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2051-6 [7697593.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1817-9 [7728744.001]
  • [Cites] Thromb Haemost. 1995 Jan;73(1):59-65 [7740497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8205-9 [7667269.001]
  • [Cites] Thromb Haemost. 1995 Jul;74(1):282-90 [8578473.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 2):H2091-104 [9374741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2251-62 [10479670.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1159-67 [16142335.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):395-403 [16556013.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):237-48 [1423816.001]
  • [Cites] FASEB J. 1992 Apr;6(7):2397-404 [1563592.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):10-6 [420161.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):683-8 [15375485.001]
  • [Cites] Thromb Haemost. 2004 Sep;92(3):627-33 [15351861.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Chest. 2004 Aug;126(2):601-7 [15302749.001]
  • [Cites] J Thromb Haemost. 2006 May;4(5):1056-62 [16689759.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Nat Med. 2004 May;10(5):502-9 [15098027.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2743-50 [15087389.001]
  • [Cites] Thromb Haemost. 2003 Sep;90(3):549-54 [12958625.001]
  • [Cites] J Thromb Haemost. 2003 Sep;1(9):1972-6 [12941039.001]
  • [Cites] Carbohydr Res. 2002 Nov 19;337(21-23):2239-43 [12433488.001]
  • [Cites] Thromb Haemost. 2002 Oct;88(4):686 [12362244.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):930-6 [12083498.001]
  • [Cites] Semin Thromb Hemost. 2002 Feb;28(1):29-38 [11885023.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3302-9 [11071621.001]
  • (PMID = 17139378.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL052622-09; United States / NHLBI NIH HHS / HL / R01 HL052622; United States / NHLBI NIH HHS / HL / R01 HL062244; United States / NHLBI NIH HHS / HL / HL062244-07; United States / NHLBI NIH HHS / HL / HL052622-09; United States / NIGMS NIH HHS / GM / GM038060-19; United States / NIGMS NIH HHS / GM / R01 GM038060; United States / NIGMS NIH HHS / GM / R01 GM038060-19; United States / NHLBI NIH HHS / HL / R01 HL062244-07
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Enoxaparin; 0 / Factor Xa Inhibitors; 0 / Heparin, Low-Molecular-Weight; 0 / Lipoproteins; 0 / NA-LMWH; 0 / lipoprotein-associated coagulation inhibitor; 9001-26-7 / Prothrombin; 9002-04-4 / Factor IIa
  • [Other-IDs] NLM/ NIHMS75576; NLM/ PMC4114246
  •  go-up   go-down


97. Shimada Y, Tai H, Tanaka A, Ikezawa-Suzuki I, Takagi K, Yoshida Y, Yoshie H: Effects of ascorbic acid on gingival melanin pigmentation in vitro and in vivo. J Periodontol; 2009 Feb;80(2):317-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The effects of ascorbic acid on melanin formation were evaluated in vitro in B16 mouse melanoma cells and three-dimensional human skin models.
  • RESULTS: Ascorbic acid significantly inhibited tyrosinase activity and melanin formation in B16 mouse melanoma cells (P <0.01 and P <0.05, respectively).

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Gum Disease.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186973.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Gels; 0 / Melanins; 2V52R0NHXW / ascorbic acid 2-O-glucoside; EC 1.14.18.1 / Monophenol Monooxygenase; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


98. Margalit A, Sheikhet HM, Carmi Y, Berko D, Tzehoval E, Eisenbach L, Gross G: Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin. J Immunol; 2006 Jan 1;176(1):217-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we explored membrane-anchored beta2m as a platform for cancer vaccines using as a model MO5, an OVA-expressing mouse B16 melanoma.
  • [MeSH-major] Cancer Vaccines / immunology. Epitopes, T-Lymphocyte / immunology. Melanoma, Experimental / immunology. T-Lymphocytes, Cytotoxic / immunology. beta 2-Microglobulin / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365413.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Epitopes, T-Lymphocyte; 0 / H-2 Antigens; 0 / H-2Kb protein, mouse; 0 / beta 2-Microglobulin
  •  go-up   go-down


99. Kim YJ, Yokozawa T: Modulation of oxidative stress and melanogenesis by proanthocyanidins. Biol Pharm Bull; 2009 Jul;32(7):1155-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated the inhibitory property of PAs on melanogenesis and oxidative stress of cultured B16F10 melanoma cells (B16 cells) utilizing both oligomer and polymer PAs that were isolated from freshly crushed persimmon peel.
  • Thus, our present work produced evidence that in B16 cells, the anti-melanogenic capacity of PAs as shown by the inhibition of tyrosinase and melanin synthesis likely occurs through the suppression of oxidative stress by the ability of PAs to modulate total RS, O(2), NO , ONOO(-), lipid peroxidation, and redox balance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571377.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Melanins; 0 / Proanthocyanidins; 0 / Reactive Nitrogen Species; 0 / Reactive Oxygen Species; EC 1.14.18.1 / Monophenol Monooxygenase; GAN16C9B8O / Glutathione
  •  go-up   go-down


100. Shimoda H, Tanaka J, Shan SJ, Maoka T: Anti-pigmentary activity of fucoxanthin and its influence on skin mRNA expression of melanogenic molecules. J Pharm Pharmacol; 2010 Sep;62(9):1137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Inhibitory effects on tyrosinase activity, melanin formation in B16 melanoma and skin pigmentation in UVB-irradiated guinea-pigs were evaluated.
  • KEY FINDINGS: Fucoxanthin inhibited tyrosinase activity, melanogenesis in melanoma and UVB-induced skin pigmentation.
  • [MeSH-minor] Animals. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Guinea Pigs. Male. Melanoma / prevention & control. Mice. Mice, Hairless. Monophenol Monooxygenase / genetics. Monophenol Monooxygenase / metabolism. Phytotherapy. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. RNA, Messenger / metabolism. Receptor, Melanocortin, Type 1 / genetics. Receptor, Melanocortin, Type 1 / metabolism. Receptor, Nerve Growth Factor / genetics. Receptor, Nerve Growth Factor / metabolism. Receptors, Endothelin / genetics. Receptors, Endothelin / metabolism. Receptors, Prostaglandin E, EP1 Subtype / genetics. Receptors, Prostaglandin E, EP1 Subtype / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Ultraviolet Rays

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20796192.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Melanins; 0 / Plant Extracts; 0 / RNA, Messenger; 0 / Receptor, Melanocortin, Type 1; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Endothelin; 0 / Receptors, Prostaglandin E, EP1 Subtype; 0 / Xanthophylls; 06O0TC0VSM / fucoxanthin; EC 1.14.18.1 / Monophenol Monooxygenase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down






Advertisement